[{"article": "More than 1.5 billion people worldwide suffer from chronic pain, with lower back pain being the most frequent condition affecting 23 to 26 percent of the population.\nThe new treatment, called HF10\u2122 therapy, uses proprietary high frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz.\nGiven the prevalence of chronic pain, high frequency SCS is an exciting advance for our patients.\u201d\n\n\n\nSCS is an increasingly common therapy that delivers electric pulses to the spinal cord, through a small device implanted under the skin, for difficult to treat chronic pain in the trunk and limbs.\nIdentifying a new intervention that does not rely on paresthesia to mask pain is novel to SCS and has the potential to improve pain relief and quality of life for these complex patients.\nNewswise \u2014 Chicago \u2013 Chronic back and leg pain sufferers in search of better pain relief options may have a new choice.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t address the costs of newer, high-frequency SCS vs. traditional SCS. Since traditional SCS seems to be commonly used, it should be possible to provide some estimate of what the device and the implantation procedure cost. It would be nice if the release had also addressed potential insurance coverage for either device.", "answer": 0}, {"article": "So any energy-consuming process usually turns off the moment the body doesn't need it.\"\nScientists had previously observed that cinnamaldehyde, an essential oil that gives cinnamon its flavor, appeared to protect mice against obesity and hyperglycemia.\nTheir findings, which appear in the December issue of the journal Metabolism, indicated that cinnamaldehyde improves metabolic health by acting directly on fat cells, or adipocytes, inducing them to start burning energy through a process called thermogenesis.\nAnd because it is already used widely in the food industry, it might be easier to convince patients to stick to a cinnamon-based treatment than to a traditional drug regimen.\nNow, before anyone goes dumping tons of extra cinnamon in their egg nog in hopes of keeping holiday-season pounds at bay, Wu cautioned that further study is needed to determine how best to harness cinnamaldehyde's metabolic benefits without causing adverse side effects.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There are no costs discussed in this news release.\u00a0 However, this study is extremely preliminary, and it is not known how cinnamaldehyde would be sourced if this were to become a drug.\u00a0 Cinnamon is a common spice available on any grocery shelf, is fairly inexpensive and is made from tree bark.\u00a0 It can also be chemically synthesized, but the natural source is the least expensive.", "answer": 2}, {"article": "\u201cIt\u2019s a promising result from an interesting data set,\u201d he said.\nThe letter was in response to heavy marketing by companies touting the benefits of their programs based on scant scientific data.\nThe program is now incorporated in Posit Science\u2019s BrainHQ.com brain training program.\nThe new analysis was by Dr. Jerri Edwards of the University of South Florida, whose mentor, Dr. Karlene Ball of the University of Alabama at Birmingham, sold her rights to the program to Posit Science.\nEdwards said she was frustrated with the scientific debate, which is one reason she agreed to present her findings before they were published.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not explicitly discuss the costs of brain game software programs. It does give Posit Science\u2019s BrainHQ.com as an example so the reader can probably find out the cost rather easily.", "answer": 0}, {"article": "The National Institute on Deafness and Other Communication Disorders estimates that 26 million Americans between the ages of 20 and 69 have high-frequency hearing loss.\nMED-EL expects that the SYNCHRONY EAS Hearing Implant System will be available in the coming months.\nUNC participated in the EAS System clinical trials and implanted the device in more patients than any other hearing center that participated.\nBut a hearing implant system that just received FDA approval will now meet that previously unmet need and benefit those patients, according to Harold C. Pillsbury, MD, chair of the Department of Otolaryngology/Head and Neck Surgery at the UNC School of Medicine.\n\u201cThe technology is remarkable and so were the results.\u201d\n\nThe implant relies on two auditory technologies \u2013 the SYNCHRONY cochlear implant that stimulates the auditory nerve for high-frequency hearing loss and the EAS audio processor, which has a built-in acoustic amplification for low-frequency hearing loss.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Neither the release nor a company web site, nor a Google search turned up information about the cost of the approved device. There are almost always out-of-pocket costs associated with implants, even when insurance coverage is good.", "answer": 0}, {"article": "We need to be proactive in our approach.\"\nThis led researchers to further develop a risk prediction tool to better identify which patients undergoing a hip replacement may be at higher risk for dislocation, and then implement a treatment algorithm to help reduce that risk.\nA novel risk assessment tool helps identify which patients undergoing total hip replacement may be at higher risk for an implant dislocation after surgery, according to a new study from researchers at NYU Langone Health and described in the Best Poster in the Adult Reconstruction Hip at the American Academy of Orthopaedic Surgeons (AAOS) 2018 Annual Meeting in New Orleans.\nThe researchers reported only one dislocation in this high-risk group (or 0.5 percent of high-risk patients), compared with 3.1 percent in the previous group not assessed with the risk assessment and treatment algorithm.\nFuture studies aim to examine how the algorithm affects long-term outcomes and clinical benefits in patients at high risk for dislocation.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There are three costs not mentioned in this news release that are critical in evaluating the relevance of this unpublished study.\nFirst, the release could have compared the costs of \u201cdual mobility cup\u201d hip transplants vs. conventional implants. We\u2019re told the former are \u201cmore expensive\u201d but it would be helpful to know by how much, since the study suggests dual mobility cup transplants may be indicated in patients at high risk for dislocation.\nSecond, the study is based on a \u201cnovel risk assessment tool\u201d which suggests pre-operative scans in the sitting and standing positions. How much does this cost? It\u2019s not mentioned.\nThird, how much money could potentially be saved by reducing the need for \u201crevision surgeries\u201d in patients whose implant becomes dislocated? It is unlikely that this will reduce costs overall given the small number of individuals who may require repeat surgery, even in this high risk group. Thus, the question is whether this is a cost-effective strategy or not.", "answer": 0}, {"article": "Guidelines from the American Cancer Society and other organizations recommend that women age 30 and older are screened using Pap smears and tests for the human papillomavirus, or HPV.\nRoland pointed to the extra costs women may incur to get childcare and make it to the doctor\u2019s office \u2014 plus the costs to a strained healthcare system of ordering more tests.\nIn that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\n\u201cA woman should know what test is being used,\u201d said Dr. Mona Saraiya, a co-author on the new study.\n\u201cA woman should say, \u2018What screening tests are you doing on me?\u2019\u201d\n\nAnd if doctors want women to come back again next year, women should ask them why, Saraiya said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story referred to \u201cextra costs women may incur to get childcare and make it to the doctor\u2019s office \u2014 plus the costs to a strained healthcare system of ordering more tests.\u201d", "answer": 1}, {"article": "During the last three months of 2008 \u2014 the most recent data available that allowed a comparison among robotic, open and laparoscopic surgeries \u2014 more than half of all prostate removals involved robot-assisted surgery.\nEmphasis should be lmited on procedure, he said, as opposed to surgical skill.\nThe trade-off was the cost, with robotic prostate removal costing about $10,000 on average, roughly $700 more than laparoscopic surgery and $1,100 more than open surgery.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\n\u201cYears ago, this was thought to be the be-all-end-all operation, particularly with prostate surgery.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Much of the focus of the piece was on costs.", "answer": 1}, {"article": "When a hip bone breaks because of osteoporosis, the fracture usually involves either the ball at the top of the femur or the narrow neck just below the ball.\nFor instance, they started out with a history of more fractures, so the comparison isn't valid.\nStill, the accumulating evidence that there is a risk of these serious, unusual fractures associated with bisphosphonates is getting a lot of attention in the medical community.\nThe idea is that perhaps they'd get the osteoporosis benefit without the risks of osteonecrosis and unusual fractures.\nAmid all the debate, many specialists are wondering if women on bisphosphonates should take a \"holiday\" from the drug from time to time.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story gives no cost information. We wish the story had given the yearly cost of at least one of these therapies, and even some comment on the high cost of recovery from a typical hip fracture for the thousands of elderly women who suffer them.", "answer": 0}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Unfortunately, like the earlier Times\u00a0story, the WSJ story doesn\u2019t mention costs, either those associated with taking prescription or over-the-counter drugs to treat insomnia or those associated with cognitive behavioral therapy. The closest the story comes to mentioning cost is when it notes that one problem with the use of prescription sleep aids is that insurance may not cover long-term use; this would have been an obvious point at which to note how expensive these drugs can be. The story suggests that cognitive behavioral therapy can be effective after as few as two sessions, but it doesn\u2019t say how many sessions the average patient requires, how expensive those sessions are likely to be nor how likely it is that insurance would cover this type of therapy.", "answer": 0}, {"article": "Other medications, including raloxifene and a class of drugs called aromatese inhibitors, do much the same thing, though the Food and Drug Administration has not yet approved aromatese inhibitors for this use.\nThis is an evolving field, and our goal is to better discern who is at high and low risk of breast cancer and develop a greater range of prevention strategies.\u201d\n\nAn individual risk analysis should prompt conversation between doctor and patient about the potential benefits and the risk of the therapy.\n\u201cThe discussion should include the specific risks and benefits associated with each chemopreventive agent,\u201d according to ASCO.\ncould reduce their risks for invasive cancer by approximately 30 to 50 percent.\u201d On the other hand, these drugs don\u2019t suit everyone, and they are not without risks of their own.\n\u201cAt the 1.67 percent high-risk threshold,\u201d Georgetown\u2019s Lin says, \u201cevery woman age 62 and older would be [considered] high-risk.\u201d That might lead to a situation in which millions of women would be encouraged, unnecessarily,to consider this therapy, along with its potential harmful effects.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions that these drugs are \u201ccovered\u201d by the Affordable Care Act, and that \u201cwomen with a high risk for breast cancer and a low risk for side effects who try this therapy will not incur out-of-pocket costs.\u201d We\u2019ll call this nod in the direction of costs sufficient for a satisfactory rating, but the story does not discuss these drugs\u2019\u00a0prices or the cost of repeated office visits to monitor their side effects. There was an opportunity here for a rich discussion about incurring some upfront cost for a potential for downstream cost savings in terms of lower cancer rates and reduced need for treatment.", "answer": 1}, {"article": "According to Cancer Research UK, eight out of 10 children with leukemia in Britain now survive for five years or more, compared with one in 10 in the late 1960s.\n\u201cEven though this is still lab-based ... it validates the idea of developing small molecules against epigenetic switches,\u201d he said in an emailed comment.\n\u201cWe urgently need better ways to treat children with more aggressive forms of leukemia, such as MLL,\u201d said Lesley Walker, CRUK\u2019s director of information.\n\u201cThis ... is an exciting new avenue for drug discovery which we hope will be useful for other types of cancer in addition to MLL-leukaemias,\u201d said Tony Kouzarides of the Wellcome Trust/CRUK Gurdon Institute at Cambridge University, who co-led the study.\nUsing I-BET151 to treat leukaemias in mice and human cancer cells in a lab, the researchers found that the chemical could halt the disease, paving the way for more research to be done in first-stage, or so-called Phase I, human trials.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given the extremely early stage of research, we can understand why cost was not discussed.", "answer": 2}, {"article": "\u201cThis is literally on the cutting edge of where the field is,\u201d Dr. DeKosky said.\nAnd when \u2014 researchers optimistically are saying \u201cwhen\u201d these days \u2014 drugs are shown to slow or prevent the disease, the thought is that people will start having brain scans or spinal taps for Alzheimer\u2019s as routinely as they might have colonoscopies or mammograms today.\nFor now, Dr. DeKosky said, the days when Alzheimer\u2019s could be confirmed only at autopsy are almost over.\nAlthough the latest PET scans for Alzheimer\u2019s are not commercially available, the spinal fluid tests are.\nNearly every person with Alzheimer\u2019s had the characteristic spinal fluid protein levels.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nNot only does this story fail to mention the costs of spinal taps, PET scans or other potential tests for\u00a0 biomarkers of early Alzheimer\u2019s Disease, it does not alert readers to the possible financial consequences of a test indicating that a person is likely to develop Alzheimer\u2019s Disease, such as problems obtaining health, life or disability insurance, job discrimination or other consequences. Although recent federal legislation protects Americans against discrimination based on genetic information, the law does not apply to spinal taps, PET scans or other biomarker tests that do not reveal genetic information. \nPerhaps the NYT\u00a0will pursue this as a next-day folo. \n\u00a0\nReference:\nGenetic Information Nondiscrimination Act (GINA) of 2008\n http://www.genome.gov/24519851 ", "answer": 0}, {"article": "\u201cYou don\u2019t want to treat a patient if he doesn\u2019t need to be treated,\u201d Shipley said.\nAmong men whose cancer showed signs of coming back after their prostate was surgically removed, adding a drug that blocks androgen receptors to radiation treatments halved their death rate from prostate cancer over the subsequent 12 years.\nMen with medium-grade tumors and those who may not have had their entire cancer removed during surgery also survived significantly longer if they received the drug.\nProstate cancer recurrence happens in about 30 percent of patients after surgery.\nA commonly used drug could dramatically increase survival rates for men who have to fight prostate cancer twice.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No treatment costs are shown, for either radiation or hormone blocking. According to a 2015 study in the journal Future\u00a0Oncology, the average cost per hospital stay was $12,268, while outpatient clinic visits tallied about $4,364 per visit (surgery and radiation). However, given multiple visits, the typical prostate cancer patient can expect a lifetime cost of about $110,000.\nBut adding in hormone blockers, also called androgen deprivation therapy, according to a 2007 study in The Journal of Urology, can double the cost of a man\u2019s care.\u00a0Newer drugs that are being used now might cost more, too.", "answer": 0}, {"article": "The most common side effects of atezolizumab included skin rash, colitis, and low thyroid hormone.\nAlthough the rate of severe side effects was higher with the combined modality treatment than with chemotherapy alone (68% vs. 57%), it had a manageable safety profile, consistent with known safety risks of the individual therapies.\nThis is the first phase III trial of an immunotherapy-based combined modality treatment to show a significant improvement in progression-free survival in advanced squamous NSCLC, according to the authors.\nAt 12 months, cancer had not worsened in twice as many patients who received atezolizumab plus chemotherapy compared to those who only received chemotherapy.\nOutcomes for only two of the groups, however, are being reported in this presentation:\n\nOutcome data for the third treatment group, which received atezolizumab with a slightly different chemotherapy regimen (carboplatin and paclitaxel), are not yet available.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost, which is an important point in this case, because each treatment with atezolizumab (Tecentriq) can cost more than $8000. These patients were treated every three weeks, which would produce bills upwards of $12,000 per month.", "answer": 0}, {"article": "This slowly progressive enlargement of the prostate can make urination difficult or painful and send men trudging to the bathroom many times during the day and night.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\nNor does it lead to cancer.\ncan lead to serious health problems for some.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs associated with any of the treatment options mentioned \u2013 a glaring omission given the variation in costs among the approaches discussed. ", "answer": 0}, {"article": "\u201cWe want to alleviate the suffering and get them back to their life,\u201d he said.\nBut, according to Zarate, more research is needed on how to use the drug in the safest and most effective way.\nRight now, medications available for treating either major depression or bipolar illness can take weeks, or even months, to work, notes Dr. Carlos A. Zarate Jr. of the National Institutes of Health in Bethesda, Maryland, one of the researchers on the study.\nIt\u2019s also a drug of abuse, at much higher doses than those used in Zarate\u2019s research; while patients in the current study received about 50 milligrams during a 40-minute period, a dose too low to induce anesthesia, recreational users of ketamine, known as \u201cSpecial K,\u201d may take hundreds of milligrams per week.\nAnd as a person waits for their medications to kick in, he added, they will continue to have difficulty working and coping with social and family life; they may even be having thoughts of suicide.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of costs. Our medical editor on this story advises that ketamine is not particularly expensive. However, it is administered by infusion so there will be costs associated with adminstration.", "answer": 0}, {"article": "Gastrointestinal symptoms are the hallmark of NCGS \u2014 although some people also complain of fatigue or a foggy head.\nFor those of us who care about our health but, let\u2019s face it, like a nice baguette, it seems worth asking: Is there any actual health benefit to gluten avoidance?\nIf you are cutting out gluten for any other reason, all that will happen is you\u2019ll feel the same, but without the pleasure of bread that tastes like bread.\nBut let\u2019s say you take heart in the first of these studies and now believe that avoiding gluten will make some people feel better even though they don\u2019t have an allergy or celiac disease.\nFor those of you keeping track at home, that means that while 30 percent of Americans are trying to cut gluten from their diet, probably at most only 1 percent of Americans may have NCGS.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the story does mention that there are now a broad range of gluten-free foods on the market, it does not discuss the increased costs associated with those products.\u00a0One additional sentence would have made a really good story a little bit better.", "answer": 0}, {"article": "Paul Delios of Saugus, Mass.\nHutcher says it's now about one in 1,000, which makes it less deadly than most major surgeries.\nDr. Hutcher says the operation itself can take type 2 diabetes - which has ballooned in this country - and throw it into complete remission.\nYet most people who have this operation do not get skinny.\nIt used to be that roughly one in 100 people died from this operation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The segment reports that the surgery costs about $25,000 and is not always covered by insurance. ", "answer": 1}, {"article": "Other immunotherapy approaches are in the pipeline, along with fancier versions of drugs to block the hormones that feed prostate cancer.\nNobody yet knows just how to explain these results.\nThe primary mystery is how Provenge extends life, since it doesn't shrink prostate tumors, as far as anyone can tell.\nSo it's not surprising there's a lot to be learned, and that it's pretty pricey.\nBut, after all, Provenge is just the first cancer immunotherapy on the market.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story itself only says \"it\u2019s pretty pricey.\"\u00a0 But those words provide a hyperlink to another NPR\u00a0story that discloses the drug cost as $93,000.\u00a0 It would have taken the same amount of space to just state the cost in the current story.\u00a0 Why make people click away to get the cost in another story?\u00a0 Is the need to improve click rates driving this? Regardless, we\u2019ll give the story the benefit of the doubt on this. \u00a0", "answer": 1}, {"article": "This can cause less blood to reach the brain and, in rare cases, may also trigger a stroke if plaque breaks off and becomes lodged in the small vessels in the brain.\nThe patients who are at high risk are candidates for surgery, he said.\nOf course, anyone with symptomatic carotid stenosis is a candidate for immediate surgery, Topakian said.\nThis would include people with high cholesterol, high blood pressure or heart disease, he said.\n\"This test could be a good tool to identify the right patients for surgery,\" Topakian said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story included no discussion of costs.\u00a0 How much would these methods cost?", "answer": 0}, {"article": "\"I had a really bad headache,\" Aldrich told Regan.\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\nBut for students such as Aldrich, who don't know their baseline, extra caution is the doctor's order.\nNearly one in five high school athletes suffers a concussion each season, Regan points out.\nHe wants her to avoid exerting herself, physically and mentally, because a \"bump on the head\" is a lot more dangerous than it sounds.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\nThere is no mention of the costs associated with using the Impact system or other neurocognitive tests, in either dollars or time (e.g. training, testing, and interpretation). The story does not attempt to compare costs of this system with other systems that might help a physician determine when an athlete should return to play.\n", "answer": 0}, {"article": "It's a barrier between enamel and the soft tissue that contains all the blood vessels and cells,\" Celiz explained.\nInstead of the current dental materials used on fillings, which are toxic to cells, the new approach harnesses stem cells instead.\nWhen dental pulp disease and injury happen, a root canal is typically performed to remove the infected tissues, explained Dr. Adam Celiz, Marie Curie Research Fellow at the University of Nottingham.\nIf successful, a treatment like this could someday offer significant benefits for millions of dental patients each year.\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address the potential cost of this procedure and how it might compare to a root canal, but this is important to consider since root canals are very expensive, and presumably a procedure involving stem cell regeneration would be, too. According to one consumer information website, a root canal costs between $585 to $1,400 depending on the location of the dentist\u2019s office and the type of tooth. Those estimates do not include restorative procedures such as crowns, posts and cores, and fillings, which can cost hundreds or thousands of dollars more.", "answer": 0}, {"article": "To compare the effects of linagliptin to glimepiride (the most commonly used sulphonylurea), the researchers conducted a double-blind study over the course of two years.\nThe results of a larger, ongoing study currently underway may help resolve the issue of whether the newer drug is worth the extra money, Weiss said.\nOne expert said patients and doctors may still have to balance the superiority of linagliptin against its higher cost in comparison to older drugs.\nAnd since hypoglycemia \"can have substantial negative clinical consequences\" in terms of risk for death, illness, mental function and poor quality of life, preventing it is crucial, study co-author Baptist Gallwitz, of Tubingen University Hospital, said in a news release.\nNone of the patients had responded to metformin alone.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We were glad to see the story at least mentioned the cost issues, although we would have preferred some actual dollar figures. It says, \u201cOne expert said patients and doctors may still have to balance the superiority of linagliptin against its higher cost in comparison to older drugs.\u201d And later it says, \u201cmillions of Americans suffer from type 2 diabetes, so \u2018cost issues favoring sulfonylureas may be the only reason for preferring continued sulfonylurea use,\u2019 he added.\u201d\u00a0 Barely satisfactory.", "answer": 1}, {"article": "For tips and recipes, visit LoveOneToday.com or follow HAB on Facebook, Twitter, Pinterest and YouTube.\n\"Fresh avocado, as part of a balanced diet, and as a cholesterol-free substitute for solid fats, can help be part of the solution for maintaining normal cholesterol levels,\" says Nikki Ford, PhD, Director of Nutrition, Hass Avocado Board.\nOn the heels of this advice, a new meta-analysis (considered the best evidence and an unbiased overview of the body of knowledge on a specific topic), published in the Journal of Clinical Lipidology, adds to the growing body of research that supports the use of avocados in lieu of solid fats (and foods that have higher saturated fat content) to significantly change lipid profiles.\nA 12-member board representing domestic producers and importers of Hass Avocados directs HAB's promotion, research and information programs under supervision of the United States Department of Agriculture.\nFunding for HAB comes from Hass avocado producers and importers in the United States.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Avocados are expensive and that should be acknowledged when advising consumers to add 1 or 1.5 daily to their diets. According to the Hass Avocado Board\u2019s own website, the average retail price of a conventionally grown avocado is $.89, while an organic one is $1.52.\u00a0 A family of four could potentially spend $25 to $42 a week on avocados alone were they to adopt the release\u2019s recommendation.", "answer": 0}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs. However in this context, where the cost of treatment is relatively\u00a0low, this criterion seems less relevant.", "answer": 2}, {"article": "\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\n\"Colonoscopy is still recognized as the gold standard - the best way to catch this cancer at an early stage.\n\"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\nThe company currently has two product candidates in clinical development: ECP, which is expected to enter Phase 3 clinical trials in early 2017, and the \"C-bar\", a novel product candidate for chronic constipation, which is currently being studied in a Phase 1b clinical trial.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Although the prep is still moving through clinical trial stages, the anticipated cost of this new formulation will be front-of-mind among folks reading stories about it.\u00a0 The earlier this kind of information is offered the better.", "answer": 0}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given that the premise of the story is explaining there is no benefit to taking these supplements, we\u2019ll rate this N/A. That said, it would have been interesting to explore the cost-savings for people if they decide to stop buying calcium and vitamin D.", "answer": 2}, {"article": "\"In most cases, a recall doesn't mean you have cancer,\" says Hubbard, a biostatistician at the Group Health Research Institute in Seattle.\nWomen can halve their risk of a call-back for a false-positive if the interpreting radiologist has previous mammograms for comparison, the researchers found.\nThey found a small but not significant increase in the chance that women diagnosed with breast cancer had a more advanced case if they underwent screening every other year instead of every year.\nThe task force says the decision to start regular, biennial mammograms before age 50 should be an individual choice based on each patient's situation.\nAnd 7% to 9% will be told they should have a biopsy because of something suspicious that turns out not to be cancer, the researchers concluded.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the financial costs of screening mammography & false-positive recalls & biopsies were not included in the study, readers would benefit from being reminded that recall mammography & biopsies increase patient financial costs.", "answer": 0}, {"article": "\"Our thinking is similar to how you might approach a battle against two enemies,\" said Dr. Soran.\nThe study was selected for the society's \"Best of ASCO,\" an effort to condense the research \"most relevant and significant to oncology\" into a two-day program to increase global access to cutting-edge science.\n\"We've shown that surgery to remove the primary tumor--either through lumpectomy or mastectomy--followed by standard therapy, is beneficial over no surgery.\"\nDr. Soran began the trial in 2007, ultimately recruiting a total of 274 women newly diagnosed with stage IV breast cancer from 25 institutions.\nThis research was primarily funded by the Turkish Federation of Societies for Breast Diseases.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs in the release. This would be an easy addition, given how common these types of surgeries are.", "answer": 0}, {"article": "In the raw analysis, mothers who skipped the supplement were more than 2.1 times more likely to have a child with autistic disorder compared with mothers who took the supplement.\nYou can read a summary of the study and the editorial on the JAMA website.\nBut not all mothers were equally likely to take folic acid supplements.\nIt\u2019s unclear how these findings apply to mothers and children in the United States.\nNor did they find any link between fish oil supplements and risk of ASDs.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 No discussion of costs, but since folic acid supplement pills cost only a few cents each, the omission is not important.", "answer": 2}, {"article": "\u2022 Cardiovascular disease affects one in six Australians or 4.2 million people.\nNewswise \u2014 Thousands of people can take heart as new research from the University of South Australia shows a dairy-enhanced Mediterranean diet will significantly increase health outcomes for those at risk of cardiovascular disease \u2013 and it\u2019s even more effective than a low-fat diet.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\n\u201cThese needs are unmet in the traditional MedDiet, which makes it difficult for people to adopt in the long term.\n\u201cLiving in Australia, we have different dietary requirements, notably a need for more calcium to protect against osteoporosis,\u201d Wade says.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t discuss the costs of adhering to a dairy-supplemented Mediterranean diet. However, many people know the costs for typical Mediterranean diet food items like nuts, fruits, and fish and dairy products like milk and cheese.", "answer": 2}, {"article": "Drug list (formulary): To see a list of covered drugs for the plan you\u2019re considering, use the drop-down menus below.\n\nIf your employer is offering coverage, contact HR for the pharmacy plan name.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost of treatment not mentioned.", "answer": 0}, {"article": "The skin, she says, \"has been irreparably damaged by the stretch [and it] doesn't shrink down like the rest of the body does.\nThe cost of contouring can run into the tens of thousands of dollars, depending on how many procedures are needed.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nBut there's a catch often not understood by those who undergo the procedure: Once they lose the weight the surgery helps them lose, there may be more surgery to come -- surgery that is costlier and riskier and that requires a longer recovery time than the original operation.\nThe solution: plastic surgery to remove the extra skin, a set of procedures known as body contouring.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The costs of contouring are presented as tens of thousands of dollars; in addition, mention is made that they are not necessarily covered by insurers.", "answer": 1}, {"article": "Studies have shown that people with cancer are more prone to blood clots and that people with blood clots are at increased risk of cancer.\nHowever, they need to be confirmed, and the optimal dose, timing, and duration of use needs to be worked out, he says.\nMen who took aspirin gained the greatest benefit, Choe says.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nAspirin and other anticlotting medications carry risks of their own, chiefly bleeding, Zietman says.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nCost was not mentioned in this story. Now you might say that the focus is on aspirin, which readers are likely to already know is relatively inexpensive. However, the story should have highlighted the cost differential between aspirin and some of the other drugs included in the study, such as warfarin and Plavix, since those on the inexpensive aspirin derived the most benefit. And it should be noted that even drugs that cost little for each pill may cost the nation a substantial amount if long-term use is recommended for many millions of individuals", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s too early to discuss\u00a0how much one of these experimental drugs might cost. But the article could have reported something about the estimated costs of currently caring for these\u00a0patients. It\u2019s also worth noting that if a drug is ever approved, it will cost Medicare a bundle.", "answer": 2}, {"article": "The researchers found a 19-percent reduction in non-fatal heart attacks among participants who took aspirin compared to those who did not.\nBut the blood-thinning drug doesn\u2019t appear to cut the chances of dying from the disease, at least not enough that researchers can say for certain.\n\u201cA blanket recommendation that everybody should take an aspirin is not a good idea.\u201d\n\u201cI don\u2019t think this paper is inconsistent with previous work.\u201d\n\nNichols, who was not involved in the study, said aspirin is clearly beneficial for people who\u2019ve already had heart disease, and that it also seems to help those at high risk.\nThe question then becomes finding out what your risk of heart attack is in the first place, which your doctor can help with.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll accept the brief mention \u2013 at the very end of the story about aspiring being \u201ccheap\u201d and \u201ccost effective for men over 45.\u201d\u00a0 We all know it\u2019s cheap.\u00a0 But it doesn\u2019t hurt to include a few words about cost and cost-effectiveness.", "answer": 1}, {"article": "It can be very unpleasant.\nActual costs to patients, payers and health systems are anticipated to be lower as WAC pricing does not reflect discounts, rebates or patient assistance programs,\u201d it said.\nStudies of about 2,000 people showed Dupixent injections resulted in clear skin or nearly clear skin for about two-thirds of those who tried it, and it reduced itching sharply in 40 percent.\nIt\u2019ll cost $37,000 a year but the drug\u2019s makers, Regeneron Pharmaceuticals and Sanofi, have stressed that\u2019s the wholesale price and make a point of saying there will be programs to help people pay for it.\nIn a nod to the sensitivity around drug prices, the company stressed that there is no single price for the drug.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a barely passing satisfactory rating\u2013the story did disclose the cost of $37,000, but overlooked some important details when it then tried to explain that manufacturers think the actual cost to patients will be lower.\nThe full picture is more complicated. Drug company patient-assistance programs \u2014 which help patients cover co-payments and other out-of-pocket costs \u2014 are abhorred by economists because they shield patients from treatment costs and undermine the ability of insurers to steer patients to less expensive options.\nIn addition, an accompanying video states \u201ca billion and a half dollars\u201d was spent developing the drug but doesn\u2019t point out that the purported development cost is small compared with the potential profits. If all 300,000 people the manufacturers of this drug say are \u201cmost in need of treatment options\u201d receive this drug, the total cost could be as high as $11 billion a year, funds that must be diverted from other healthcare priorities or come from higher premiums or taxes. That broader analysis was missing in this story.\nAn independent draft analysis showed dupilumab did improve health outcomes compared to usual care but with additional costs, and that the drug did fall below commonly cited standards for cost-effectiveness. Still, the study relied on some uncertain variables and found the drug was most cost effective for patients with severe conditions.", "answer": 1}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no cost data. Gilenya costs $8,210 for a 30-day supply, according to the web site drugs.com.", "answer": 0}, {"article": "An estimated 5.4 million Americans have Alzheimer's disease, the most common form of dementia, according to the Alzheimer's Association.\nNone are highly accurate, and some are costly and not practical to use on a widespread basis, experts say.\nThe research results on the new test are published online in PLoS ONE.\nHis test is one of numerous such tests under study, says Heather Snyder, PhD, a spokesperson for the Alzheimer's Association, who reviewed the research results.\nHe is also founder of Durin Technologies Inc., the company that is developing the test.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story includes a tentative estimate of what this sort of blood test might cost if it is approved.", "answer": 1}, {"article": "RA Nash et al.\nNIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases.\nDuring the procedure, doctors collect a participant\u2019s blood-forming stem cells, give the participant high-dose chemotherapy to deplete the immune system, and return the participant\u2019s own stem cells to rebuild the immune system.\nFive years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression of disability, relapse of MS symptoms or new brain lesions.\nThe trial, called HALT-MS, was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There\u2019s no mention of the cost of stem cell transplants. We could find no reliable cost estimate online, but several sources including the American Cancer Society put the price in the hundreds of thousands of dollars. Transplants that use a patient\u2019s own stem cells, known as autologous transplants, are cheaper than those that use donor cells.", "answer": 0}, {"article": "No one knows why some women have this capability and others do not, but for those who lack it the Inovio vaccine is \"giving our immune system a little boost,\" Kim said.\nKissing is not known to deliver this STD.\nThe researchers did not observe any side effects.\nKim said the next phase results should be out at the end of 2013; then comes a larger phase 3 trial with about 500 patients, to be concluded around 2016 or 2017.\nAlso, 18 people is a small number for examining the effects of a medication.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable; too early in development process to discuss costs.", "answer": 0}, {"article": "Sept. 8, 2010 -- People who take cholesterol -lowering statin drugs to reduce heart disease risk may also be cutting their risk for developing the painful inflammatory joint disease rheumatoid arthritis .\nStudy researcher Gabriel Chodick, MD, called the risk reduction \"important and meaningful,\" but he says more research is needed to confirm the association.\n\"But one important message is that people who have been prescribed them should adhere to treatment.\nThe study appears in the September issue of the journal PLoS Medicine.\nBut it is not driven by inflammation, so statin use is not as likely to affect its development or progression.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\n\n\nThe story does not mention the costs of statin therapy, which include not only the drug itself but also ongoing testing and other monitoring. For some patients, statins are part of a lifelong treatment regimen. In those cases in particular, the costs can really add up.", "answer": 0}, {"article": "However, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\nAs for the new paper this week, which suggests that three times as many men would be diagnosed each year with metastatic prostate cancer if it weren\u2019t for PSA testing, that study is published in the journal Cancer \u2014 and its numbers deserve a little explanation.\nStill, the real crux of the debate on PSA testing is the second issue: the possible negative effects of screening.\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nMany health experts think that\u2019s too much risky treatment to justify the results.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We reviewed three stories that covered this new retrospective study on PSA screening. None of them discussed the costs involved in the PSA tests or the subsequent treatments.\n\u00a0", "answer": 0}, {"article": "WASHINGTON (Reuters) - An experimental drug being developed to fight influenza may fight a common but little-known virus called parainfluenza virus, researchers and the company said on Friday.\nAdding parainfluenza to its approved indications would provide a unique and potentially large market for San Diego-based NexBio.\nMoscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\nThere is no treatment or vaccine for parainfluenza.\nThe researchers said that means patients with flu-like symptoms could get the drug without the need for a test to show whether their infection was caused by influenza or parainfluenza.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this drug is not on the market, a discussion of cost is not warranted.\u00a0\u00a0 ", "answer": 2}, {"article": "The study found that 78 percent of patients reported being pain-free or having adequate relief within 15 minutes of receiving high-flow oxygen, compared with 20 percent of patients after they received high-flow air.\nThe National Pain Foundation has more about cluster headache.\nHigh-flow oxygen also provided better pain relief at 30 and 60 minutes.\nNo serious harmful side effects were reported after high-flow oxygen treatment, according to the report published in the Dec. 9 issue of the Journal of the American Medical Association.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story fails to mention costs for either oxygen treatment or the conventional treatment, an injection with sumatriptan. ", "answer": 0}, {"article": "Will they be habit forming?\nExperts note that findings from animal studies do not always hold up in human trials.\nMerck already has one such drug, suvorexant, under review by the U.S. Food and Drug Administration (FDA).\nThat means, theoretically, fewer side effects and perhaps less of a tendency to be habit forming, Thorpy explained.\nMore than 30 million Americans struggle to get a good night's sleep, and about one-third of these use drugs to help the process, the study authors pointed out.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Given the cost of the newer sleep aids (in excess of $250/month), the cost of a new drug is an important consideration.\u00a0 While the study in question was conducted in rats, a close relative of DORA-22 is under consideration for approval by the FDA.\u00a0 It is for that reason we think that cost should have been part of the storyline.", "answer": 0}, {"article": "Scientists have slowed down the ageing process by implanting stem cells into the brains of animals, raising hopes for new strategies to combat age-related diseases and extend the human lifespan.\nThe work, described as a tour de force and a breakthrough by one leading expert, suggests that ageing across the body is controlled by stem cells that are found in the hypothalamus region of the brain in youth, but which steadily die off until they are almost completely absent in middle age.\nThe next step is to create human neural stem cells in the lab for testing.\nThe latest investigation from the US team pinpoints which cells are important and how they might work.\n\u201cHowever, if the mechanism is fundamental, you might expect to see effects when an intervention is based on it.\u201d\n\nPrevious experiments had already hinted that the hypothalamus, an almond-sized part of the brain in humans, played some role in the ageing process, but what it was remained unclear.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll give the story a \u201cN/A\u201d in this category since it makes clear early on that this research is in the earliest of stages, done in an animal model, and says clearly that clinical trials are a future hope. This is way too early to consider costs which, we assume, would be substantial.", "answer": 2}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains the cost of $294,000 a year for this drug.\u00a0 And it describes the drug company\u2019s financial assistance plan.", "answer": 1}, {"article": "\"That's the great thing about proton therapy.\"\nWhile the proton therapy market is expected to more than double by 2018, with an estimated 300 proton therapy rooms, Jongen's Brussels-based company IBA is working on a smaller and cheaper model they hope will make proton therapy more accessible.\nHealth practitioners have been searching for a magic bullet that goes straight to the source of the cancer -- and everything from monoclonal antibodies, which carry cancer drugs direct to cancer cells, to straight surgery to cut out tumors have been used with varying degrees of success.\nAt the moment, fewer than 1% of cancer patients are treated with proton therapy, but Jongen is hopeful that smaller and cheaper machines will be the game changer.\nThe other drawback is that the cyclotron is not cheap.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the cost of building a proton beam treatment center ($125 Million) but it does not speak to the real issue of the costs of treatment directly. Medicare reimbursement for proton beam treatment of prostate cancer is about $32,000, whereas IMRT is reimbursed at about half that amount.", "answer": 0}, {"article": "\u201cIt\u2019s just not a good operation,\u201d he asserted.\nThe surgeon removes part of the stomach, and the remaining \u201csleeve\u201d-like stomach is attached to the final section of the small intestine; that puts even greater limits on the body\u2019s absorption of calories and nutrients.\nTwo years after surgery, duodenal switch patients had lost more weight: about 50 pounds more, on average.\nThere was no evidence that surgery improved longevity over the next seven years.\nThat, he added, makes the risks of duodenal switch seem even less worthwhile.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention in this lengthy story of the costs of the two procedures or insurance coverage. Readers need this information, and the fact that the duodenal switch may not be covered by most insurance. The total cost of gastric bypass is about $20,000.", "answer": 0}, {"article": "But for relapsed ovarian cancer, surgery is usually not an option.\nMoreover, the extra chemotherapy seemed to worsen the quality of life.\nBut she stopped short of saying it should be eliminated, saying that in any event, patients would not accept that.\nThe finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\nBut others would prefer to know.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not describe the cost of CA-125.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": " The rabbits were given a supplement. Is this supplement available and if so, what does it cost? We\u2019re not told. \u00a0", "answer": 0}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nNew research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nWorking with colleagues at the Mayo Clinic in Rochester, Minnesota and the MD Anderson Cancer Center in Dallas, Texas, Michael Chuong, MD, an assistant professor of radiation oncology at the school, compared two kinds of X-ray radiation with proton therapy, an innovative, precise approach that targets tumors while minimizing harm to surrounding tissues.\nThe researchers looked at nearly 600 patients and found that proton therapy resulted in a significantly lower number of side effects, including nausea, blood abnormalities and loss of appetite.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release mentions that UMD is currently building a proton beam center that will cost $200 million. However, there\u2019s no information about the actual cost of treatment with proton therapy compared with other radiation treatment techniques. Proton therapy is significantly more expensive. The American Cancer Society noted in 2013 that \u201cMedicare pays about $19,000 for a full dose of standard radiation therapy for prostate cancer, but it pays nearly double for proton therapy \u2013 more than $32,000.\u201d", "answer": 0}, {"article": "Also low are haddock, pollock, flounder and sole, Atlantic croaker, crawfish, catfish, trout, Atlantic mackerel, crab and mullet.\n\u201cIt may be that the issue is re-evaluated and there is no change.\u201d\n\nMercury levels in our oceans are on the rise due to an increase in industrial mercury emissions.\n\u201cThe benefit of having (omega-3 fatty acids) in your diet really exceeds the likely risk of contamination.\nBut a federal panel has reignited the debate about the benefits and risks of eating tuna and other seafood during pregnancy.\nExperts agree that seafood is a rich source of important nutrients, and that most of us don\u2019t eat enough of it.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The gist of this story is to compare the health effects of tuna vs. other types of fish during pregnancy. We don\u2019t think there\u2019s a significant cost difference between tuna and most other types of fish \u2014 at least not one that we\u2019d expect to see addressed in an article like this. So while the story could have mentioned the relatively high cost of seafood compared with other nutrient-rich foods, we won\u2019t penalize it for not addressing the cost of tuna. We\u2019ll call it Not Applicable.", "answer": 2}, {"article": "\"Adolescence is the key time for bone growth.\nThough swimming and cycling have proven health benefits, the scientists said their study \"raises a question\" about whether they are good for bone development due to the non-weight bearing training - and they say young swimmers and cyclists could benefit from more weight-bearing exercise in training regimes.\nIn a study comparing adolescent footballers to swimmers, cyclists and a control group of boys not involved in regular sport, scientists at the University of Exeter found football led to significantly better bones after one year of training.\nDespite the many health benefits of cycling and swimming, the study found little difference in bone development between cyclists, swimmers and the control group.\nPlaying football can improve bone development in adolescent boys, new research shows.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release provides no discussion of costs. While a soccer ball isn\u2019t terribly expensive, the boys involved in this study weren\u2019t casually kicking the football around the back yard or the neighborhood soccer pitch; they were \u201caspiring professionals who played as much as nine hours a week,\u201d according to the study\u2019s lead author. That level of training almost guarantees that the boys were participating in traveling soccer teams, and while the costs might be lower in the United Kingdom, where the study was conducted, in the United States, playing on a traveling soccer team is far from cheap. A September 2015 USA Money article described a California family who spent $17,500 annually for their four boys to play competitive soccer, including club fees of $675 per month, $1,500 per year for a private coach, more than $1,000 for cleats and other gear, $100 participation fees per child per tournament, along with the costs of tournament travel. Those costs, of course, might well be higher than average, but the bottom line is that the news release provides no information about the likely cost of having a child playing competitive soccer/football.", "answer": 0}, {"article": "At the same time, we studied a small sample of patients, so our results should be interpreted with caution,\" Fried added.\nSo it's difficult to generalize this study's results to other diseases that affect memory, she said, and the research didn't show if effects of temporary deep brain stimulation last beyond the study period.\nAlthough the results are still preliminary, the method may potentially hold promise for boosting memory in patients with early Alzheimer's disease, the researchers said.\nWEDNESDAY, Feb. 8, 2012 (HealthDay News) -- Deep brain stimulation, a technique used to treat Parkinson's disease and certain psychiatric disorders, appears to provide some memory-enhancing benefits, researchers report.\nStimulation of the entorhinal cortex -- a region considered crucial to transforming daily experience into lasting memories -- produced the improvement, the researchers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This line of research is so preliminary that we won\u2019t criticize a story for omitting cost estimates. However, as the story notes, similar technology is used to treat some people with Parkinson\u2019s disease and other disorders, so the story could have told readers how much those applications cost.", "answer": 2}, {"article": "Anton P. Porsteinsson, MD, Professor of Psychiatry at the University of Rochester School of Medicine and Dentistry and Director of the Alzheimer's Disease Care, Research and Education Program at the University of Rochester in Rochester, NY, and an investigator in the North American Phase 3 clinical trial, commented: \"The genetically-defined population of APOE4 carriers has an 8-12 fold increased risk of developing AD and has more rapidly progressive disease, usually becoming symptomatic a decade earlier than non-carriers of the APOE4 genotype.\n\"To our knowledge, this is the first time that the clinical benefits of an amyloid-targeted agent have been associated with the number of APOE4 alleles in Alzheimer's patients.\nOur clinical expertise and technology platform is focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.\n\"These newly-published findings form the basis for the design of our Phase 3 program, and further support our company's commitment to advance ALZ-801 into pivotal studies in APOE4/4 homozygous AD patients who represent up to 15% of AD patients1.\n\"APOE4/4 homozygous AD patients are especially challenging since they are known to have the highest burden of amyloid pathology in cerebral cortex and blood vessels, which explains their susceptibility to ARIA-E with some amyloid-targeted treatments.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release is about clinical research on a compound that is not available yet to patients outside of an experimental setting. Even so, we wish the release had some cost context on the drug. When (or if) it debuts in the future, what might it cost?", "answer": 0}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nThere's more on RNA interference at the Howard Hughes Medical Institute.\nThe precision of the process is crucial to limiting side effects, the researchers said.\nThe experiment proceeded just as planned, as biopsies later showed.\nBut the work that nabbed the prize was done in worms -- a far cry from humans.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs were discussed, which is understandable at this early stage of research.\u00a0 Not applicable.", "answer": 2}, {"article": "Also, there was increased expression of an enzyme involved in blood vessel formation and a protein involved in nerve cell survival and growth.\n\"The LIPUS therapy is a non-invasive physiotherapy that could apply to high-risk elderly patients without the need for surgery or anaesthesia, and could be used repeatedly,\" says Shimokawa.\nThe researchers conclude that their study, recently published in the journal Brain Stimulation, provides the first experimental evidence that whole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects by enhancing specific cells related to dementia's pathology.\nThis limits the types of drugs and cell therapies that could be made available to treat dementia.\nFocusing LIPUS treatment on a region in the brain called the hippocampus, which is involved in memory, has also been found to improve dementia in mice, but the details of how it does this need to be more fully investigated.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We don\u2019t see any dollar signs, but we mark this one \u201cnot applicable\u201d because the research is at such an early phase and just making the transition from animal models to clinical trials. And though it\u2019s unreasonable to speculate how much a LIPUS device or treatment may cost, if it pans out to be safe and effective, ultrasound scans can cost anywhere between about $70 and $500 per body part in 2018 dollars, according to a 2005 study.", "answer": 2}, {"article": "Pregnancies are usually about 40 weeks, and a premature birth is when a baby arrives three or more weeks early.\nThe test, if it does turn out to work in clinical trials, would be cheaper than ultrasound, said Quake.\n\"Those molecules will circulate in the blood for some time, they can be measured, and you can see the contributions from essentially every tissue in the body,\" senior investigator Stephen Quake told BuzzFeed News.\nThe study was funded by the March of Dimes and other nonprofit sources, although Quake and his colleagues have filed for a patent on the test.\n\"When you are pregnant you can see the contribution from the placenta and the fetus,\" said Quake, a professor of bioengineering and applied physics at Stanford University in Palo Alto, California.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Experimental\u00a0health\u00a0tests\u00a0don\u2019t\u00a0have public price tags. However,\u00a0this\u00a0story\u00a0gives\u00a0readers\u00a0a rare and helpful ballpark\u00a0estimate, and one that compares it to an alternative (ultrasound):\u00a0\u201cIt might be tens or hundreds of dollars, rather than thousands,\u201d a study author told BuzzFeed.", "answer": 1}, {"article": "\"It's very stressful because you're sleep-deprived, you're not eating right ... you're working back-to-back shifts and you're trying to catch up on sleep but you can't,\" Dalechek said.\nGuille said offering web-based therapy routinely to medical residents could be beneficial, if her research results are confirmed in a broader study.\nThe research involved about 200 medical interns \u2014 residents in their first post-graduate year, which is often one of the most intense periods of doctor training.\nPrevious research has shown benefits from similar web-based therapy in other settings.\nIt used a free online program developed at the National Institute for Mental Health Research at the Australian National University in Canberra.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says the study involved a free online program developed in Australia. Knowing that it is free may be incentive enough for some individual doctors or their hospitals to look into it \u2014 so this is useful information.", "answer": 1}, {"article": "In 2009, the U.S. Food and Drug Administration warned Matrixx Initiatives to stop selling its widely used supplement Zicam after more than 130 users reportedly lost their sense of smell.\nStill, with an infection that currently has no good treatment and leads to an estimated 275 million lost work days a year in the U.S., well, what a difference a day makes.\nThe bottom line: After seven days of treatment, those taking the supplements had less than half the chance of still being sick.\nWhile the episodes usually aren\u2019t serious, the resulting visits to the doctor alone cost the U.S. an annual $7.7 billion, according to the new report.\nA typical adult has a few colds every year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story says that the supplements can be bought \u201cfor a few dollars,\u201d which is more than the WebMD story noted. Even better, though, this story talked about the costs in work days missed and lost productivity from the common cold.", "answer": 1}, {"article": "In those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nWhile it\u2019s available over the Internet, she said her team had only looked at hospital-based test performance.\nBianchi said one study had estimated the blood test costs about 255 pounds in the UK (about $413), all included.\nRosser, however, chalked that up to the ethical issues it raises.\n\u201cBut it should only be used by families that are at risk for sex-linked diseases.\u201d\n\nBianchi said she owns stock in Verinata Health, a company that is developing cell-free fetal DNA tests for Down syndrome, although that company had no role in the new study.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story mentions the estimated cost of test, but does not note that consumers can get the test without a doctor\u2019s involvement in the US.", "answer": 1}, {"article": "Men who had the highest levels of lycopene in their blood were 55% less likely to have a stroke, compared with men who had the lowest levels of the antioxidant in their blood.\nTomatoes are not the only food that is rich in this antioxidant.\nTomatoes are rich in the antioxidant lycopene.\n\u201cThe results support the recommendation that people get more than five servings of fruits and vegetables a day, which would likely lead to a major reduction in the number of strokes worldwide, according to previous research.\u201d\n\nOther studies have shown that high lycopene levels may be linked to a reduced risk of certain cancers.\nDuring that time, 67 men had a stroke.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The cost of tomatoes, or other sources of lycopene, is not in question.", "answer": 2}, {"article": "Learn more about type 1 diabetes from the American Diabetes Association.\nThe hydrolyzed formula is also considerably more expensive than standard formula, experts point out.\nThe current study was randomized and double-blind (meaning neither the parents nor the researchers knew who was getting what), and compared regular baby formula to one that was made easier for babies to digest because the proteins were broken down (extensively hydrolyzed).\nBoth Lee and Harlan stressed that there is currently no definitive evidence to suggest that the use of standard cow's milk formulas leads to an increased incidence of diabetes compared to breastfeeding.\nAccording to Knip, the take-home message from the study is that \"it is possible to reduce considerably the initiation of the diabetes disease process in at-risk children in a simple and safe way: weaning to an extensively hydrolyzed formula.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the extensively hydrolyzed formula is more expensive than standard formula; however, the authors should have indicated how much more expensive hydrolyzed formula is compared to regular formula. Monthly cost comparison of two formulas would have been appropriate as this may be a deciding factor for many families who choose not to breastfeed, or who are weaning.", "answer": 0}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states that the LVAD device costs $80,000, and that the total cost, including implant surgery, is over $150,000. ", "answer": 1}, {"article": "The American Orthopaedic Society for Sports Medicine (AOSSM) is the premier global, sports medicine organization representing the interests of orthopaedic surgeons and other professionals who provide comprehensive health services for the care of athletes and active people of all ages and levels.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nSAN DIEGO, CA - Knee pain in active patients over 40 is often difficult to treat but according to researchers presenting their work today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Annual Meeting in San Diego utilizing a special kind of allograft may be a step in the right direction.\nAOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids.\nGreatest changes were seen in the ability of patients to perform Sports and with improvement in healthful daily activity.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are not addressed at all. A 2007 article from Orthopedics Today\u00a0estimated the cost of an allograft at approximately $10,000. The relevant cost may have gone up or down in the intervening years, but is likely still considerable \u2014 and well worth mentioning.", "answer": 0}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The release does not mention costs. One may assume there is no cost to sleep deprivation but the deprivation in the studies was mostly monitored in inpatient facilities, which can be expensive.", "answer": 0}, {"article": "We need to assess these options before jumping to possible universal screening.\"\nAmong the 5,798 children who would not have been screened, nearly 10% had elevated LDL cholesterol levels (above 130 mg/dL), according to the study, published in the August issue of Pediatrics.\nFurther, Neal says, the findings apply not only to heart-disease risk but also to the risk of diabetes, since high cholesterol at a young age is a strong predictor of prediabetes and diabetes.\nRather than calling for all youngsters to have their cholesterol tested, which would entail considerable expense on the national level, Dr. Ralph Sacco, president of the American Heart Association (AHA), suggests looking more critically at current screening guidelines.\nIndeed, of all the children in the study whose LDL levels were above 160, one-third were in the group who would not have been screened.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story includes one comment that national screening would be expensive, but it does not provide a dollar figure. It also does not mention the potential cost of treatments. Cost is clearly relevant to the story. The researchers blame the lack of health care insurance for the high proportion of parents and grandparents of these children who have never had a cholesterol test. The story does not address the issue of how families would pay for ongoing treatment.", "answer": 0}, {"article": "Cocaine use is widespread in the Western World.\nThe results of this pilot study, published in the peer-reviewed journal European Neuropsychopharmacology, suggest that this may become an effective medical treatment for patients with cocaine addiction, although a larger trial is needed to confirm the initial findings.\nAs far as we know, this work represents the first clinical report indicating that rTMS treatment results in significant reduction in cocaine use.\nIn addition, 69% (11/16) patients) in the experimental group showed no relapse to cocaine use, whereas only 19% (3/16) patients) in the control group showed a similar positive result (the results are adjusted for patients who dropped out of the trial).\nIt is also important to emphasize that, in this study patients were seeking treatment for their cocaine addiction in a hospital setting: the group studied, albeit small, was a \"real world\" sample.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "While the release clearly labels this work as preliminary, the overall inference of the news is that this is a potential successful treatment for cocaine addiction. But there is no mention at all of the potential cost of using this new approach.The FDA approved rTMS for major depression in December 2008. A 2013 article in Scientific American said a typical rTMS therapy session cost $300. In this study, patient volunteers underwent eight sessions which would have totaled $2,400 if paying out of pocket.\nThe costs of the drugs used to treat persons in the control group are well-known so at least those costs could be compared to that of the magnetic stimulation treatments to give readers an idea of whether the two approaches were financially comparable.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a131601S24.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explains that \u201cThe filtration device costs hospitals $10,000 and each treatment requires an $800 filter \u2013 expenses that should be more than offset by lower hospital bills because of shorter stays.\u201d ", "answer": 1}, {"article": "Women who carry a defective gene on one X chromosome can compensate with the good copy on their other X chromosome, but they bequeath the defective copy to half their children.\nDr. High is listed as a co-author of the report because her laboratory helped monitor the patients and provided proof for regulators that the virus would not insert its human gene into the patients\u2019 sperm and make the change hereditary.\nThe patient cannot be injected again with the same virus because his immune system is now primed to attack it.\nOne patient, a geologist, had a good response at first, but his level of Factor IX has declined to 1 percent of normal, the level at which the disease kicks in.\nThe virus used by Dr. Nathwani\u2019s team, known as adeno-associated virus-8, generally stays outside the chromosomes, so it should not present this problem.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job noting the possible costs of this approach ($30,000 for a single treatment) and places it in the context of current costs ($300,000 annually).\u00a0 With an estimated incidence of hemophilia B at about 5 per 100,000 males, the cost of treating the disease worldwide is a important piece of the story.", "answer": 1}, {"article": "The shortage has eased, but some supply issues remain.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\nFor every 100 people on balanced fluids, there was one fewer death or severe kidney problem.\nSince there are about 30 million people hospitalized in the U.S. alone each year, \u201cthere are tens or hundreds of thousands of patients who would be spared death or severe kidney problems by using balanced fluids instead of saline,\u201d said one study leader, Vanderbilt\u2019s Dr. Matthew Semler.\nIVs are one of the most common things in health care.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "In comparing the costs of normal saline vs. balanced fluids, the article states \u201cthe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive.\u201d\nThis is sufficient for a satisfactory rating, but readers should be aware that even a difference of a few pennies per bag would have a significant impact at the institutional level, and a massive impact on the national level.", "answer": 1}, {"article": "\"All drugs of abuse operate using some shared pathways.\nAll of these states include chronic pain -- either directly or indirectly -- in the list of approved medical conditions for marijuana use, according to Bradford.\nThe details of the medical cannabis laws were found to have a significant impact on opioid prescription patterns, the researchers found.\nThe studies, published Monday in the journal JAMA Internal Medicine , compared opioid prescription patterns in states that have enacted medical cannabis laws with those that have not.\nThe researchers found that states that allow the use of cannabis for medical purposes had 2.21 million fewer daily doses of opioids prescribed per year under Medicare Part D, compared with those states without medical cannabis laws.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not mention how much it costs to use marijuana to treat pain or whether medical marijuana is covered by private health insurance, Medicare or Medicaid.", "answer": 0}, {"article": "The study, funded by the Canadian Institutes of Health Research and the Allergy, Genes and Environment Network (AllerGen NCE), was published in the journal Microbiome, along with an editorial in Nature.\nIn other words, even if the dog had been given away for adoption just before the woman gave birth, the healthy microbiome exchange could still take place.\nIt's far too early to predict how this finding will play out in the future, but Kozyrskyj doesn't rule out the concept of a \"dog in a pill\" as a preventive tool for allergies and obesity.\n\"The abundance of these two bacteria were increased twofold when there was a pet in the house,\" said Kozyrskyj, adding that the pet exposure was shown to affect the gut microbiome indirectly--from dog to mother to unborn baby--during pregnancy as well as during the first three months of the baby's life.\nIf you need a reason to become a dog lover, how about their ability to help protect kids from allergies and obesity?\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This is not relevant because we can assume that anyone who owns a dog is likely aware of the cost of housing, feeding and maintaining that animal and those amounts can be quite considerable.", "answer": 2}, {"article": "Chronic diseases of aging, like diabetes, hypertension, heart problems, cancer, joint disorders and Alzheimer\u2019s, are all believed to have inflammation in common.\nWe are able to point, with a much higher resolution picture, at aging and the things that should be markers for inflammation.\u201d\n\nThe key will be to figure out when the inflammatory response starts to spiral out of control.\nIn the meantime, following the example of caffeine-drinking adults with lower levels of inflammation \u2014 by having a cup of joe or two \u2014 might be a good idea.\nThe goal isn\u2019t to make every trace of inflammation disappear, the scientists stress.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t address cost. However, the story focuses almost exclusively on coffee consumption \u2014 and most readers can be assumed to be familiar with the cost of coffee. We\u2019ll rate this as not applicable.", "answer": 2}, {"article": "\u201cC.\nThough the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.\n\u201cWhat I like about this paper is that it validates the upper-GI route and demonstrates that you can get very good cure rates without doing a colonoscopy.\u201d\n\nThat\u2019s important because colonoscopies and the anesthesia required for the procedure can put a lot of stress on a person\u2019s body and can be complicated for the people most at risk for C. difficile infections, Hohmann noted\n\nKao\u2019s study also showed that people found FMTs far less unpleasant when the poop came in a pill.\nAn emerging treatment for a common hospital-acquired infection could be (slightly) less gross in the future.\nThe 116 patients used in this study may have been selected in part because they were ideal candidates for FMTs, Dr. Elizabeth Hohmann noted, but she said the paper is solid overall.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of pointing out one advantage of the pill approach compared to delivery via colonoscopy\u2013the reduced cost. \u201cThere was a significant difference in cost. Though the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.\u201d", "answer": 1}, {"article": "Non-small cell lung cancer constitutes about 85-90% of lung cancer cases.\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\nTheir study is published in the Dec. 24/31 issue of the journal Nature.\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs are discussed. But we can understand that since the story is based on an early phase of research \u2013 so early that the question might be about its newsworthiness. ", "answer": 2}, {"article": "No prior studies showed zinc lozenge use -- even up to 150 mg per day -- might cause harm aside from bad taste or constipation, Hemila said, and the most recent trial on zinc acetate indicated no significant differences between zinc and placebo groups in adverse effects even though the daily zinc dose was 92 mg.\n\nDr. Lisa Winston, an epidemiologist at San Francisco General Hospital, praised the study as a \"pretty good synthesis of the data,\" although she noted that the trials Hemila reviewed involved small numbers of participants.\nAllowing the lozenge to dissolve instead of swallowing it seemed to provide a therapeutic effect.\nSince then, more than a dozen studies have been carried out, but data on the trace mineral's effectiveness has been mixed.\nTUESDAY, Aug. 2, 2011 (HealthDay News) -- There's still no cure for the common cold, but there may be a way to shorten its misery: A new study suggests that higher doses of zinc lozenges in certain formulations may cut the length of colds by more than 40 percent.\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention cost. But zinc lozenges are not expensive, costing perhaps $5 \u2013 $10 for a course of treatment.", "answer": 0}, {"article": "\u201cOnce again pregnant women are being told it\u2019s O.K.\nDr. Malden C. Nesheim, chairman of the institute\u2019s committee and a provost emeritus at Cornell, said, \u201cWe are quite cautious because the studies we looked at are not controlled for all the variables, and we can\u2019t distinguish between the effects from omega-3\u2019s or replacement of other foods in the diet.\u201d\n\nThe National Oceanic & Atmospheric Administration had requested the institute\u2019s report because it said consumers were confused about how much and what kind of fish they should eat.\nreports to address the risks of mercury in tuna,\u201d said the consumer organization, \u201cwe are also concerned that both reports dismiss concerns about PCB\u2019s in most fish.\u201d\n\n\u201cThese reports are urging Americans to eat more seafood as if it were a crisis,\u201d Dr. Goldberg said.\n\u201cFortunately, Environmental Defense and Monterey Bay Aquarium, who specialize in both health and environmental fish issues, provide advisory cards for choosing fish, and no one can manage this without one.\u201d\n\nThe Environmental Defense list is at oceansalive.org and the Monterey Bay Aquarium\u2019s is at mbayaq.org/cr/seafoodwatch.asp.\nFor those who eat more fish, both reports advise eating a variety of species to reduce the level of contaminants.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article did not report information about the costs of fish (from 63 cents to $2.59 per week, according to the JAMA study), but readers can easily find these on their own if they don\u2019t know them already.", "answer": 2}, {"article": "Leaps in augmented-reality technology are being used to help people with severely low vision gain back enough sight to function, and then some.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nBut when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The WSJ reveals that each visor-headset costs $10,000, and even notes how \u201cmost insurance doesn\u2019t cover it.\u201d There\u2019s also some back-and-forth viewpoints about that steep cost, which is helpful to readers.", "answer": 1}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs.", "answer": 0}, {"article": "The additional benefit in terms of body composition came as a surprise for the research team.\nIn addition, Health Canada advises parents and caregivers to avoid direct sunlight and avoid use of sun block creams in young infants.\nA healthy intake of vitamin D in the first year of life appears to set children up to have more muscle mass and less body fat as toddlers, according to a new study published in the journal Pediatric Obesity.\nVitamin D supplementation is routinely recommended for babies until they can get an adequate amount through their diet.\nWhile there were no significant differences in body composition across the different dosage groups, the researchers found children who had vitamin D stores above the threshold recommended by the Canadian Paediatric Society (CPS) averaged around 450 grams less body fat at 3 years of age.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention cost.\u00a0 A quick online search found that the standard infant dose of 400 IU/day of Vitamin D costs about $10-15 for a three-month supply in the United States. We believe news releases should mention costs, including the cost of relatively inexpensive supplements or unusual foods, with associated health claims. Children growing up in poverty are at particular risk of obesity because their families suffer from food insecurity and often purchase the least expensive (and least nutritional) foods. Expenditures for pediatric supplements for people living well below the poverty level may mean less food on the table.", "answer": 0}, {"article": "For more information, please see www.arthrokinex.com\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nThis therapy has recently been highlighted by several professional football players traveling to Europe for treatment.\nOther NBA, MLB and NHL superstars have also utilized the treatment.\nFinally, a U.S. based company has a solution for America's professional and weekend athletes as well as those struggling with aching or arthritic joints.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This news release highlights the cost of the treatment \u2014 $2,000, compared to the price of $10,000 for an unnamed foreign competitor. The New York Times wrote a piece on a company in Germany supplying a similar treatment in 2012 when the cost of the procedure was about $7,500 out of pocket, so the news release seems to be relatively in the ballpark.\u00a0\nAlthough this new treatment may be less expensive that the foreign competitor mentioned, it is likely more expensive than steroid or hyaluronic acid injections and as a non-FDA approved treatment it is unlikely to be covered by American insurance companies.", "answer": 1}, {"article": "And when you have an episode, it is one of the most life-changing and life-re-evaluating events,\" Babin says.\nThe main benefit of the pills will be that they are easier to take.\nMeanwhile, approval of another new oral MS drug may come soon.\nIt was later reintroduced with strict monitoring requirements.\nHe is excited about the new drugs, but cautious.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No cost was discussed. ", "answer": 0}, {"article": "Some doctors say the increased rate of Caesareans is partially attributable to maternal demand: busy mothers may want to schedule their deliveries.\nNormal labor, Block says, isn't profitable (according to \"The Business of Being Born,\" a Caesarean can cost three times as much as a normal birth).\nThis, according to Lake, the executive producer of the film, and Abby Epstein, the film's director, is the right reaction: one of their messages is that C-sections should only be performed when needed to guarantee the well-being of the mother and infant, and should not be a first choice for healthy mothers.\nWolf and other natural-birth advocates say we need a better idea of what normal birth looks like, as movies and TV usually depict the process as painful and bloody.\nAlthough the United States has one the highest rates of Caesareans\u2014and of infant mortality\u2014Villar says the rest of the developed world is catching up.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story includes the note that \"Caesarean can cost three times as much as normal birth.\"", "answer": 1}, {"article": "\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nBut he said the studies called attention to the inconsistent quality of Her2 testing in many small laboratories.\nBut scientists have now gone back and retested those preserved tumor samples and found that as many as 20 percent of them were actually Her2-negative.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\nAlso, they said, it was not clear if those women were truly Her2-negative, since they had tested positive by the local laboratory.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story only says that Herceptin is \"expensive\" but it doesn\u2019t give cost estimates for the drug (about $20,000 per year) nor for the HER2 receptor testing.\u00a0 \n", "answer": 0}, {"article": "There\u2019s good evidence this happened to many \u2014 but not all \u2014 opioid painkiller users: A 2014 study in JAMA Psychiatry found 75 percent of heroin users in treatment started with painkillers, and a 2015 analysis by the CDC found people who are addicted to painkillers are 40 times more likely to be addicted to heroin.\nBut as Stanford pain specialist Sean Mackey emphasized to me, opioids should not be a first-line treatment due to the risks, and alternatives should be tried first.\nThis, then, is another key caveat to the study: Its findings shouldn\u2019t be applied to every patient.\nEven if they do have insurance, their health plan might not cover comprehensive pain care.\nSeveral of the studies were done in pain centers where they have expert programs, and those just are not widespread.\u201d\n\nIn fact, the lack of access to non-opioid strategies may be one big reason that doctors resorted to opioids in the first place.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Tapering is presumably free in and of itself, since it\u2019s a slow and gradual lessening of opioids (which a person might already be using to begin with), so we\u2019ll mark this N/A. However, it would require medical oversight and perhaps other alternative pain treatments, both of which aren\u2019t free.", "answer": 2}, {"article": "Researchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\nThe signature was found in the cerebrospinal fluid (CSF) of 90% of people with a diagnosis of Alzheimer's disease and 72% of people with mild cognitive impairment (MCI) -- a disorder that often progresses to Alzheimer's.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention direct costs or potential financial consequences of such a test.", "answer": 0}, {"article": "Nearly 800,000 Americans suffer a stroke every year, with about a sixth of them dying of it and many more left disabled.\nWhether that theoretical benefit translates into real-life benefits remains to be proven by rigorous studies, however.\nNEW YORK (Reuters Health) - A sweet tooth isn\u2019t necessarily bad for your health\u2014 at least not when it comes to chocolate, hints a new study.\nFor those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\n\u201cChocolate should be consumed in moderation as it is high in calories, fat, and sugar,\u201d she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rule this not applicable because, in general, most people have ballpark knowledge of how much chocolate costs.\u00a0 The story did not mention that dark chocolate is typically more expensive than milk chocolate \u2014 especially for the premium brands with very high concentrations of cocoa solids. A brief explanation would have been helpful.", "answer": 2}, {"article": "Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\nThe researchers are a now starting a small study in healthy human volunteers to look for effects on brain function.\nChurchill worked with Sridhar Vasudevan to filter through a library of existing drugs - the U.S. National Institutes of Health Clinical Collection - that are considered safe but do not currently have a proven use.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We couldn\u2019t find good cost information for this drug. It hasn\u2019t been on the market, for one, and the company that once had the patent on the drug is now out of business, so there are no good company filings that might shed light.", "answer": 2}, {"article": ".\nNAC is available over the counter and does not cause side effects at the doses used in the study, but it degrades quickly when stored, is contraindicated in patients with asthma, and can cause nausea at higher doses and so should always be obtained and administered under a physician's supervision.\nCurrently, there are no well-explored pharmacological treatments for patients with co-occurring PTSD/SUD.\nAlthough selective serotonin reuptake inhibitors have been approved by the FDA for treatment of PTSD, pharmacological treatments for co-occurring PTSD/SUD have yielded suboptimal results.\nAlthough these early, promising findings show that NAC reduced PTSD symptoms, craving, and depression, NAC should not be used as a monotherapy or substitute for evidence-based behavioral treatment, but instead be seen as an adjunct therapy that enhances it.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of N-acetylcysteine although it is on the World Health Organization\u2019s list of essential medicines, is available over-the-counter and is not very expensive. An online search reveals prices ranging from about $6 for 100 capsules containing 600 mg to around $12 for 50 high-dose capsules containing 700 mg.", "answer": 0}, {"article": "\"But we are optimistic that this new DNA Zika is a viable platform,\" Fauci said.\nThis kind of vaccine is much safer than ones that depend on live virus particles to foster immunity.\nThree experimental vaccines being developed by researchers at Harvard\u2019s Beth Israel Hospital and the Walter Reed Army Institute of Research had already shown promise in mice \u2014 but monkeys are a much better model of how the medicines will work in humans.\nRelated: New Study Shows Just How Tricky the Zika Virus Is\n\nThe two other experimental vaccines described in the new report also sparked an immune response in monkeys.\nRelated: Could We Nave New Zika Vaccine Soon?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Putting a cost estimate on experimental vaccines would be difficult to do, so we\u2019ll rate this N/A.\nHowever, there is an\u00a0opportunity in any story about Zika interventions to address the overall costs and financial needs. Congress, for example, has been in the news for months over its failure to earmark funds for Zika control requested by the White House and federal public health officials\u2013how would vaccine funding be affected by that?", "answer": 2}, {"article": "\u2022 Measure baseline omega-3 intake or status of study participants to determine the extent to which it confounds results.\nAn accompanying editorial in Mayo Clinic Proceedings also acknowledges the importance of the study.\nIt is a simple, inexpensive, and achievable change that most consumers need to make to optimize their health.\"\nThe study was supported by a grant from GOED, which played no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.\n\"It's also important that the observed risk reductions were even stronger in patient populations with elevated triglycerides and LDL cholesterol levels, two risk factors that affect more than one quarter of the American population.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost is only addressed in a quote from the executive director of an omega-3 industry organization, who refers to increasing one\u2019s omega-3 intake as an \u201cinexpensive\u201d lifestyle change. What does \u201cinexpensive\u201d mean? What may be cheap for one consumer could be cost-prohibitive for another. What\u2019s more, it\u2019s difficult for any reader to work out what the cost may be, because the release doesn\u2019t make it easy to determine how much of EPA or DHA one needs to take in order to see any potential benefit. It is only in the tenth paragraph, which quotes an editorial suggesting that taking \u201cat least 1 gram of EPA+DHA per day\u2026continues to be a reasonable strategy.\u201d That\u2019s still not necessarily clear for many consumers, since it\u2019s not directly linked to the benefits discussed elsewhere in the release, but it\u2019s the only reference to how much an individual might need to consume \u2014 and it\u2019s buried near the bottom of the release.", "answer": 0}, {"article": "\u201cYou have to be pretty bad to do poorly on this exam,\u201d she said.\nBut the alternative involves referring patients for a battery of neuropsychiatric tests that can take hours to complete and cost $1,000 or more.\nAlgase, who said she has no financial ties to the company, agreed to use the Cognivue in her practice about three years ago after meeting Duffy at a conference.\n\u201cI think it\u2019s a really potentially valuable tool,\u201d said Leslie Algase, an internist who tends about 2,000 patients in Rochester, at least 30 percent of whom are older than 65.\nThe test, which has been around since 1975, offers only a broad indication of cognitive abilities and fails to pick up borderline problems, she said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Reporting on any new device, test or drug should include comments about cost.\u00a0 In this case a word or two about the cost of the device, whether or not it is reimbursable under commercial insurance plans or Medicare would have been helpful.\u00a0 There is a billing code used for payment by insurance companies and Medicare (CPT 96120:\u00a0Neuropsychological testing [e.g. Wisconsin Card Sorting Test, CNS Vital Signs], administered by a computer, with qualified health care professional interpretation and report). \u00a0 The reimbursement for the\u00a0test and interpretation is\u00a0$48.\nThe story did mention that other tests can cost more than $1000, but it\u2019s not clear how much less expensive the new test would be. The story also notes that\u00a0the test could be administered without the physician present, which might indirectly cut costs and allow time for other important discussions.", "answer": 0}, {"article": "The outcomes are getting better and better.\"\nDecadron, however, can increase the infection rate, particularly in high-risk ALL patients, when given for the full 28-day induction period.\nPrior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating methotrexate.\nThe current study showed that an alternative schedule of high-dose methotrexate was superior.\nPrevious studies by the Children's Oncology Group showed that in standard risk ALL patients--those with low white blood cell counts or under 10 years of age--decadron prevented relapse in both the spinal fluid and in the bone marrow.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release makes no mention of the costs of the drugs compared in this study, even though the drugs have been in use for years and are widely available.\u00a0 Since the study is a comparison of various treatments for this form of cancer, it seems relevant to offer a cost comparison as well as a comparison of efficacy. It appears that the high dose methotrexate is given over a 24-hour period, presumably in the hospital, while the standard methotrexate is given as a single dose.\u00a0 Also, the high dose methotrexate is\u00a0followed by leucovorin administration while the standard dose is not.\nAccording to the site GoodRx, the cost for methotrexate in low-dose (2.5 mg) pill form averages out to about $50 for a month\u2019s supply. Newer, injectable variations of the drug cost upwards of $500 a month for the 25 mg dose.", "answer": 0}, {"article": "In undeveloped countries, 75,000 women die from pre-eclampsia each year.\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\nSuch a \u201cmetabolic fingerprint\u201d test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\n\u201cIt would also ensure that those women are educated about the warning signs of pre-eclampsia.\nThere\u2019s no reason why women should be caught unaware in the late stages of a pre-eclampsia\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not mentioned in this story. This is partially excusable because\u00a0the diagnostic test is still under development, but, given the possibility of applying this test in low-resource settings, it would have been important for the reporter to ask the researchers for a cost range to show whether it is going to make any sense for most of the world. Many tests like this are too expensive to be applied widely, and there would be comparable tests that could be mentioned as a cost comparison.", "answer": 0}, {"article": ".\nThe number of cancers detected in women ages 40-49 was not significantly different from women ages 50-59 or 60-69.\nMore than 41,000 screening mammography exams were examined for callbacks and recall rate, biopsies performed, cancers detected, and sensitivity and specificity of screening mammography.\nThere was also a lower positive biopsy rate among women ages 40-49 compared with women over 50.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs are a huge part of the controversy on when to begin breast cancer screenings. This news release doesn\u2019t mention the cost of mammograms, but they can be substantial. One study published in the Annals of Internal Medicine found that in terms of cost-effectiveness, it was five times more cost effective to do mammograms on women over the age of 50 than women aged 40-49. This is because while the costs of mammograms stay the same, the incidence of disease is much lower in the 40-49 age group.", "answer": 0}, {"article": "The sequence is started by the release of phosphorylase kinase about 5 mins after injury, which activates over 200 genes that are involved in wound healing.\nIn a recent research paper, published in the open access journal BioDiscovery, Dr. Madalene Heng, Clinical Professor of Dermatology at the David Geffen School of Medicine, stresses that use of topical curcumin gel for treating skin problems, like burns and scalds, is very different, and appears to work more effectively, when compared to taking curcumin tablets by mouth for other conditions.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nIn recent years, the medicinal value of curcumin has been the subject of intense scientific studies, with publication numbering in the thousands, looking into the possible beneficial effects of this natural product on many kinds of affliction in humans.\nDr. Heng uses curcumin gel for burns, scalds and other skin conditions as complementary treatment, in addition to standard treatment usually recommended for such conditions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Since there is no discussion of costs in the news release, we give it a Not Satisfactory rating here.\nA Google search reveals that curcumin gel is available for purchase, mostly in natural food stores and through alternative medicine websites. A 2-oz tub of \u201cCurcumin Gel For Face And Body\u201d from Omnicure sells for about $89. Topical curcumin is also available as a cream, in which a 4-oz. bottle goes for $44.95.\nOther companies also market and manufacture topical curcumin gel, but the researcher in this study owns Omnicure shares (see our conflict of interests section).", "answer": 0}, {"article": "For older people who fracture a hip, the prognosis is grim: a third or more die within a year and only about 1 in 5 return to their pre-injury level of function.\n\nA new approach to care could mean it doesn\u2019t have to be that way.\n\nMore hospitals are putting hip fracture patients on a fast track from the emergency room to the operating room,...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss costs, and this is an important oversight considering how expensive inpatient surgery is. Presumably this fast-track surgery is less expensive since it reduces time spent in the hospital, but we\u2019re not giving any specifics.", "answer": 0}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Researchers have only tested chondroitinase ABC (ChABC) on animals and it\u2019s understandable that costs would not be discussed at this point.\u00a0 ", "answer": 2}, {"article": "For more information about our products and organization, visit http://www.\nThe implant procedure is minimally invasive, has few complications, and produces significant and lasting improvements in pain, disability, and quality of life.\nBased on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment.\nThe minimally invasive SIJ implant approach evaluated in this trial has been cleared by the US Food and Drug Administration.\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t discuss costs for the implant procedure. Although \u201cminimally invasive,\u201d surgical treatment options can still run into tens of thousands of dollars. Not all insurance providers cover SJF procedures. Some cover it for certain conditions but not others. The procedure was recently approved for coverage by Medicare and by Medicaid in some states.", "answer": 0}, {"article": ".\nFounded by two Stanford University computer graduates, the company has initiated an international fasting group on Facebook; at last count, there were 3,500 members.\n\u201cThere\u2019s a sizable demand, but the hype around efficacy far exceeds available evidence,\u201d notes Doraiswamy, adding that, for healthy young people such as Silicon Valley go-getters, \u201cit\u2019s a zero-sum game.\nPlease don\u2019t take it, people!\u201d\n\nFor Burke and other brain hackers, the evidence for nootropics is strong enough.\n\u201cIt\u2019s the few who are getting ahead who are using supplements to do that.\u201d\n\nThe word \u201cnootropic\u201d was coined in 1972 by a Romanian scientist, Corneliu Giurgea, who combined the Greek words for \u201cmind\u201d and \u201cbending.\u201d Caffeine and nicotine can be considered mild nootropics, while prescription Ritalin, Adderall and Provigil (modafinil, a drug for treating narcolepsy) lie at the far end of the spectrum when prescribed off-label as cognitive enhancers.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There\u2019s no discussion of cost. We found one drug cited in this story \u2014 piracetam \u2014 online for $39.99 for 180 capsules. For those seeking a cocktail of supposed brain boosters, startup Nootrobox charges $135 for \u201call the nootropics you need to enhance your cognitive state for one month.\u201d The company explains: \u201cCognitive performance is an active, long-term investment.\u201d\n(Notably, piracetam isn\u2019t on Nootrobox\u2019s ingredient list. For more on that, read the section on availability.)", "answer": 0}, {"article": "The study found that among all opioid users, concurrent use of benzodiazepines more than doubled the risk of an emergency room or inpatient visit for a drug overdose.\nAnd since the research relied on patients who were continuously insured throughout the study period, it\u2019s possible the findings don\u2019t exactly apply to people with spottier coverage.\nFor some patients, eliminating these co-prescriptions could involve some tough trade-offs.\nGiven that the opioid epidemic has quickly turned into the deadliest drug crisis in US history, it\u2019s important \u2014 and potentially lifesaving \u2014 for doctors and policymakers to at least consider the study\u2019s findings.\nFor one, emergency room visits and inpatient admissions for opioid overdoses likely aren\u2019t a perfect one-to-one proxy for overdoses that didn\u2019t involve a trip to a doctor.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While the cost implications may be murky, the story should have at least broached the topic. Changing treatment strategies for thousands of patients could reduce costs if patients drop medications without replacing them or increase costs if patients switch to more expensive therapies. Certainly, keeping people out of ERs and hospital beds would be a savings, but it also would\u00a0cost money to transition people off these medications and use different treatments, such as therapy sessions.", "answer": 0}, {"article": "\"Transfer between hospitals takes a lot of time,\" said Turner.\nThe device's success may be found in its ability to give emergency personnel a clear answer as to whether a patient is experiencing a severe stroke.\nHe predicts that the device has the potential to be used widely by emergency personnel but also to appear in other public spaces.\nThe VIPS device requires very little training to operate compared to that required to learn standard emergency examination skills, thereby reducing the possibility of human error during emergency diagnosis.\nIf so, the VIPS device could have widespread clinical implications, helping emergency personnel decide whether to take a patient to a comprehensive stroke center or a primary stroke center for treatment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Even though the device is still in its testing phase, not discussing what the ultimate cost could be does a disservice to readers.", "answer": 0}, {"article": "Autism spectrum disorder (ASD) includes a range of conditions, including Asperger syndrome, that affect a person\u2019s social interaction, communication, interests and behaviour.\nThey point to several study limitations, such as the potential for confounding and difficulty assessing type, timing and dose of supplements.\nIt\u2019s estimated that about 1 in every 100 people in the UK has ASD.\nWomen reported their use of folic acid, iron, and multivitamin supplements at their first antenatal visit and cases of child ASD were identified from national registers.\nHowever, they say these findings \u201craise questions that warrant investigation\u201d and call for verification in randomised studies \u201cbefore recommending a change to current practice.\u201d\n\nNotes to Editors\n\n Research: Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study\n\n Journal: The BMJ\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release did not mention costs of vitamin supplements.", "answer": 0}, {"article": "1.\nPears are an excellent source of fiber (24% DV) and a good source of vitamin C (10% DV) for only 100 calories per medium sized pear.\nPears are an excellent source of fiber and a good source of vitamin C. One medium pear provides about 24 percent of daily fiber needs for only 100 calories.\nThe USDA Dietary Guidelines for Americans state that people who eat more fruit as part of an overall healthy diet are likely to reduce their risk of some chronic diseases, although little is published on the health outcomes associated with individual fruits, including pears.\nThe USA Pear Bureau continues to collaborate with researchers to commission additional studies that show the relationship between pears and positive health outcomes.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "If consumers are encouraged to eat a pear a day it would be helpful to include even a ballpark cost. Fresh pears may be available in all markets year-round but the cost rises substantially when they have to be shipped long distances.", "answer": 0}, {"article": "CT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer.\nYet there was only a slight drop in deaths from the condition over the same period, suggesting many of the clots were too small to cause harm.\n\u201cRather than an epidemic of disease, we think the increased incidence of PE reflects an epidemic of diagnostic testing that has created overdiagnosis,\u201d the researchers write in the Archives of Internal Medicine.\n\u201cRight now, it is a difficult place for the patient to be in,\u201d Wiener said.\nUsing national data, the researchers found the rate of so-called pulmonary embolisms, or PEs, nearly doubled with the introduction of a new powerful diagnostic test more than a decade ago.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No mention of cost \u2013 a signficant issue in the context of alleged overdiagnosis.", "answer": 0}, {"article": "About the UNM Comprehensive Cancer CenterThe University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius.\nNewswise \u2014 WhatA research paper published in The Lancet Infectious Diseases reported that the human papillomavirus (HPV) vaccine is safe and efficacious across a wide age range of women.\nThe study showed that women in this age group were still protected from HPV infections.\nThe international study found that it protects against HPV infection in women older than 26 years.\nHPV vaccines are expected to prevent most of these cancer cases.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The vaccine is expensive and requires three, possibly in the future two, doses. Insurance may not cover it since it is not currently recommenced for the age group studied.\n\u201cThe drug company price for either vaccine is around $130 or $140 per dose,\u201d according to the American Cancer Society, \u201cThis cost does not include the cost of giving the shots or the doctor\u2019s charge. So, it\u2019s possible that the cost for the series (3 shots over 6 months) could be $500 or more.\u201d", "answer": 0}, {"article": "Clots are often the cause of heart attacks, and health authorities urge people with symptoms to go to the hospital immediately so that doctors can use balloons and stents, or clot-dissolving drugs, to try to prevent heart damage.\nDr. Hochman emphasized that angioplasty was still the best treatment for many heart attack patients who go to the hospital early, within 12 hours of when the attack began.\nAn expert not involved in the research, Dr. Steven E. Nissen, chairman of cardiovascular medicine at the Cleveland Clinic and president of the American College of Cardiology, said the study was independent and well conducted.\nThe 2,166 patients in the study had all suffered heart attacks 3 to 28 days before, caused by a completely blocked coronary artery.\nThe median time since the heart attack was eight days.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The estimated cost for having a stent placed in a coronary artery was mentioned.", "answer": 1}, {"article": "Thanks to members Drs.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\nThere is a general consensus that the initial management of knee OA treatment should include weight loss and strengthening exercises.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\nHowever, certain aspects of treatment for knee OA are controversial.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Given the statistics on the incidence of osteoarthritis of the knee provided in the release, the cost of viscosupplementation is important. The costs of the material (technically, hyaluronic acid derivatives are medical devices) varies depending on which is chosen but costs range between $300 to $500 per injection. \u00a0Since osteoarthritis of the knee is a chronic condition, the durability of the injection is an important aspect of costs. Clinical trials suggest that when it is effective, the duration is varied ranging from weeks to up to six months.\nAccording to the American Academy of Orthopedic Surgeons web page, an organization that does not specifically endorse viscosupplementation, \u201cIf the injections are effective they may be repeated after a period of time, usually 6 months.\u201d", "answer": 0}, {"article": "The watch works through a combination of sensors and AI (artificial intelligence) techniques to potentially detect and monitor symptoms like tremors, stiffness and instability, among others, according to Microsoft.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\nThe video showed Lawton trying to draw a square with her shaky right hand, and then again, wearing Emma.\nWatson erupts in tears as she calls her mother to say this is the first time she's been able to write her name in ages.\nAI is used to classify the sensor information and elicit real-time responses on small devices like wearables.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No\u00a0price is discussed, but since it\u2019s made clear that the \u201cEmma\u201d watch is a one-off prototype, we\u2019ll mark this one as \u201cnot applicable.\u201d However, it would have been useful to mention the price range of smart watches.", "answer": 2}, {"article": "While their high blood pressure was not affected, cardiac health improved.\nI predict the same will eventually be true for thyroid hormones in a large subpopulation of cardiac patients.\nGerdes has long argued that medical opinion on thyroid treatment for patients with heart disease is largely shaped by outdated studies that used toxic doses of thyroid hormones.\n\"This low dose of thyroid hormone safely restored depressed cardiac tissue T3 levels to normal while largely preventing the accumulation of collagen, or scar tissue, resulting from sustained high blood pressure,\" said Gerdes.\n\"The studies demonstrate that we should be able to implement a similar, safe treatment and monitoring program for use in human clinical trials.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release is reporting on work done in an animal model, far removed from clinical use in humans. As such, it would be virtually impossible to tell readers precisely how much potential treatment might cost consumers. And so we won\u2019t ding the story for not including a discussion of costs \u2014 we\u2019ll rate this Not Applicable.\nThat being said, it wouldn\u2019t have been difficult to discuss costs in general. T3 is not a new drug. For example, combinations of T3 and thyroxine (another thyroid hormone) are prescribed to patients with hypothyroidism or thyroid cancer. The release could have mentioned that versions of T3 are already on the market and discussed cost at least in general terms. Is it relatively inexpensive? Expensive?", "answer": 2}, {"article": "Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors.\nThe authors note some important limitations of their study--particularly the fact that it was a review study of one hospital's experience with a relatively new procedure.\nDr. Moreira and colleagues write, \"These reported cases include our learning curve patients as we familiarized ourselves with appropriate patient selection and surgical technique.\"\nDr. Moreira adds, \"In appropriately selected cases, DTI reconstruction is a viable alternative to staged techniques requiring multiple surgeries.\"\nThe researchers believe the DTI technique may expand the options for older women, who are less likely to undergo breast reconstruction.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This news release doesn\u2019t mention the cost of either the new approach being studied (direct-to-implant, or DTI, breast reconstruction) or the widely used tissue expander/subsequent implant approach to which it\u2019s compared.\nIt also made no mention on whether Medicare would cover either procedure.  ", "answer": 0}, {"article": "Several also reported variations of spirituality, unusual peacefulness, and increased feelings of altruism.\n\u201cAnd if it\u2019s true for cancer care, then it could apply to other stressful medical conditions.\u201d\n\nBossis cautions that patients should not consume psilocybin on their own or without supervision by a physician and a trained counselor.\nReporters wishing to ask a question should e-mail their name and outlet to david.march@nyumc.org during the briefing, so they may be placed in a queue; the moderator will call on individual media to ask a question in the order names and outlets were received.\n\u201cIf larger clinical trials prove successful, then we could ultimately have available a safe, effective, and inexpensive medication \u2014 dispensed under strict control \u2014 to alleviate the distress that increases suicide rates among cancer patients,\u201d says Ross, also an associate professor of psychiatry at NYU School of Medicine.\nStudy participants, he says, experienced no serious negative effects, such as hospitalization or more serious mental health conditions.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release refers to psilocybin as being \u201cinexpensive,\u201d if and when it were to become a clinical treatment option. However, there is no basis provided for why the drug would be inexpensive or what that means relative to other treatments. Given that it is currently a banned substance, it\u2019s difficult to assess how expensive the drug would be \u2014 or in what clinical circumstances it may be used (which could affect the cost for patients).\nYou may be wondering, \u201cHow can the release further address cost, given that the relevant drug is a banned substance?\u201d One way would be to specifically note that it is difficult to estimate what the cost of psilocybin treatment would be, given that it is currently a banned substance.", "answer": 0}, {"article": "You have to be really low on your iron storage before you're going to flag as anemic.\"\nIn addition to timing, further research will be needed to determine which blood test for iron deficiency without anemia is accurate, cost-efficient and practical for routine doctor's office use.\nSekhar and colleagues hoped to determine risk factors for iron deficiency without anemia that could pinpoint which women could benefit most from this more costly testing.\nThis test should be given with hemoglobin testing to catch all young women on the spectrum of iron deficiency, Sekhar said.\nWomen are typically tested some time in their teens for anemia -- the severe form of iron deficiency -- using a quick and affordable hemoglobin test.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release mentions that existing hemoglobin tests are affordable, but that screening for iron-deficiency below the level of anemia can be costly. This squeaks by as discussing \u201ccosts\u201d but we wish figures had been offered. Is affordable $2 or $20? Is costly $100 or $500? Numbers would help readers better understand the cost implications of screening.", "answer": 1}, {"article": "Mental disorders lack what most other health diagnoses rely on: biological markers.\nIf there was a blood test for depression, it could just become part of a standard panel\u2014and thus help achieve earlier diagnoses, and in turn earlier treatment, across the board.\nDespite these exciting preliminary findings, there aren\u2019t yet any biological tests for mental illness widely used in medical practice.\nBut, if biological tests for mental illness do come to fruition, even those already living with a condition could benefit.\nIn some cases, the reason is primarily financial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no mention of costs in this piece. With the variety of tests that are being discussed, it would have been possible to at least mention a range of possible costs per test.", "answer": 0}, {"article": "Symptoms include recurring headaches, loss of appetite, blurred vision, vomiting, shifts in personality and the ability to learn, seizures and the gradual loss of speech.\nRead more: New prostate cancer DNA spit test developed by scientists\n\nEach year, glioblastoma kills around 15,000 adults in the U.S.\n\u201cFor example, we need to make sure that the therapeutic vaccine virus does not infect and kill normal neurons in humans.\u201d\n\nDr. Harry Bulstrode, brain tumor expert funded by the charity Cancer Research U.K. who is researching how Zika could be used to treat aggressive brain tumors, who was not involved in the study, told Newsweek: \"This study is another interesting piece in the jigsaw, but it is never going to demonstrate what we believe to be the really exciting properties of the virus.\nCurrently, most people diagnosed with the condition die within two years.\nThat\u2019s because glioblastoma stem cells have similar properties to neural stem cells.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This is a report of the results of a clinical trial in mice. It\u2019s too early to estimate costs for human treatment. However, some discussion of the steep, sometimes bankrupting, costs of cancer treatment is always a good idea.", "answer": 2}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t provide any cost estimate for candesartan. It did mention that there was a need to conduct analysis examining the risk to benefit ratio including costs.", "answer": 0}, {"article": "\u201cIt is important to know that Noctiva is not approved for all causes of night-time urination, so patients should discuss their symptoms with their health care provider who can determine the underlying cause of the night-time urination and whether Noctiva is right for them.\u201d\n\nNocturia (wakening at night to urinate) is a symptom that can be caused by a wide variety of conditions, such as congestive heart failure, poorly controlled diabetes mellitus, medications, or diseases of the bladder or prostate.\nNoctiva is being approved with a boxed warning and a Medication Guide because it can cause low sodium levels in the blood (hyponatremia).\n\u201cToday\u2019s approval provides adults who overproduce urine at night with the first FDA-approved therapeutic option to help reduce the number of times a night they wake up to urinate,\u201d said Hylton V. Joffe, M.D., M.M.Sc., director of the Division of Bone, Reproductive, and Urologic Products in the FDA\u2019s Center for Drug Evaluation and Research.\nNoctiva is the first FDA-approved treatment for this condition.\nNoctiva\u2019s efficacy was established in two 12-week, randomized, placebo-controlled trials in 1,045 patients 50 years of age and older with nocturia due to nocturnal polyuria.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The FDA evaluates drugs without considering the cost, which is why we give the release a pass for not mentioning the price tag. We hope the FDA could one day also comment on the projected cost of drugs and their cost-effectiveness.\nHow much will this re-purposed drug cost? We found a 5-milliliter bottle of generic desmopressin acetate on the market for $69.95. However, the manufacturer that won approval for this new use might charge significantly more when it markets the drug under the name Noctiva. The company had no comment on pricing, according to a recent report in FiercePharma.", "answer": 2}, {"article": "As many as 20 percent of American adults have some symptoms of irritable bowel syndrome, according to the National Institutes of Health.\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\n\u201cThe exciting thing about the data on linaclotide is that it improves both of those symptoms,\u201d he said.\nSome drugs that treat the pain, including opiates, can make the constipation worse, he said.\nIf the drug succeeds in a second Phase 3 trial, with results expected by the end of the year, Ironwood plans to file for regulatory approval next year.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that the new drug would likely\u00a0cost \"several dollars a day.\"\u00a0We\u2019ll call this satisfactory since we can\u2019t know exactly how much this drug will cost, but we\u2019d suggest that\u00a0a cost-per-month metric would be a better way to quantify the costs of treatment. It would allow for easier comparison with other recurring costs like\u00a0the cable or phone bill.", "answer": 1}, {"article": "Another sensor, just approved by the F.D.A.\nThe sensor doesn\u2019t control the pump but allows a diabetic to make quicker, presumably better decisions.\nThe main problem was that the sensor was simply not as accurate as a blood-glucose tester.\nI also had three sensor catheters slip out and require early replacement, which would be especially annoying to anyone paying the $35 that each sensor costs; I wasn\u2019t, because MiniMed had supplied everything free for testing, but everybody else will, since the sensors are not yet covered by insurance.\nWith each catheter intended to last just three days, the bill comes to $350 a month.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does describe monthly testing supply costs for the new device ($350). However, the article could be improved by telling readers how much the actual device costs and/or comparing this to typical blood glucose testing monitors and supplies. ", "answer": 1}, {"article": "Adults with arm or leg pain caused by a sprain, strain or fracture.\nEven for people who initially had rated their pain as a 10 (for the worst pain possible) or had broken a bone, there was virtually no difference in pain reduction between those who had and had not taken an opioid.\nData on pain came from the participants' ratings; no information on side effects was collected.\nWithin two hours, all participants reported essentially identical declines in pain, about four points on the scale.\nThe drug industry\u2019s triumph over the DEA, even as opioid-related deaths rise\n\nShingles can be intensely painful; it may also mean health problems ahead\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t addressed. As we noted when reviewing the news release, the costs of ibuprofen and acetaminophen are fairly low \u2014 but the relevant opioids are also relatively inexpensive. For the relevant dosages, the costs would be more or less comparable, with the hydrocodone/acetaminophen combination likely being the most expensive.", "answer": 0}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although there was no discussion of costs, the article was clear in stating that vaccines are\u00a0for the most part\u00a0in an early stage of development, so this omission is understandable.", "answer": 2}, {"article": "They were divided in groups of 10.\nResearchers said that the lab results identify a class of existing drugs that are likely to treat Alzheimer\u2019s by blocking a particular part of the immune response.\nBrough, however, cautioned that further research is required to identify its impact on humans and the long-term implications.\nOur research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nThe research was conducted when mice had developed memory problems.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs don\u2019t rate a mention in the story.\u00a0The drug in question requires a prescription in the United States and is expensive, ranging between $111 and $400 for a 30-day course of treatment.", "answer": 0}, {"article": "Patients with cancers of the immune system, like multiple myeloma, are especially susceptible to common infections, and a bout of the flu can lead to serious illness and even death.\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\nThe Yale researchers developed a strategy that entailed offering patients a high-dose flu vaccine followed by a second high-dose booster shot one month later.\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t mention any costs associated with the high-dose vaccine.\nThe New York Times reported last year that \u201cThe cost of the high-dose vaccine is $28.65 a dose, and Medicare covers one shot a year without a co-payment.\u201d", "answer": 0}, {"article": ".\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nCorrection: The original version of this post incorrectly named the company that is distributing the Bronchial Genomic Classifier.\nOther research is being conducted to find markers for lung cancer, though much of it focuses on substances that can be found in the blood, Spira said.\nThe current advance was a long time in coming and shows the difficulty of bringing research from the lab to the consumer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article notes that traditional means of diagnosing suspected lung cancer are costly, often involving invasive procedures and resulting complications. That\u2019s good. But it doesn\u2019t cite any range of costs, information easily available from groups like the American Thoracic Society. More significantly, perhaps, is the lack of any estimated cost for the new genomic classifier test, which was apparently readily available because it was reported elsewhere. (A Reuters story, for one, had this info.)", "answer": 0}, {"article": "While Drs.\nWhile the FAME 2 trial showed that PCI reduced urgent hospital admissions and revascularizations and likely reduced heart attacks, it did not provide evidence for a difference between PCI and medication alone in the prevention of deaths.\nThe trial was initially sponsored by St. Jude Medical, a global medical device company, until the three-year follow-up.\n\"Currently, the standard practice in North America is to prescribe medication to patients with stable coronary artery disease and avoid PCI,\" said Dr. Peter J\u00fcni, Director of the Applied Health Research Centre (AHRC) at the Li Ka Shing Knowledge Institute of St. Michael's Hospital, who is a senior author on the study.\nThe medication used in the FAME 2 trial consisted of a combination of aspirin, cholesterol-lowering and blood pressure-lowering drugs as required by current treatment guidelines.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not address the cost of adding PCI to standard medical therapy. Nor does it mention the hypothetical cost savings that might accrue from avoiding hospitalizations in patients whose PCI procedures help avert heart-related complications.", "answer": 0}, {"article": "I took her to somebody who supposedly could heal through touch,\u201d she said.\n\u201cAnd if [kids] have poor coordination in their body, they often have poor coordination in their brain -- poor coordination between their networks -- so they can't bring all these networks together to learn in the most optimal way.\u201d\n\nThe program uses a combination of sensory motor (physical) exercises and academic learning to help stimulate and strengthen the parts of the brain responsible for certain disorders.\n\u201cI thought we weren't going to get accepted to the program, and they told us they could help us and we never looked back.\u201d\n\nThe specialized learning centers, of which there are now 80 throughout the country, were developed by Dr. Robert Melillo, a neurology researcher and author of the book \u201cDisconnected Kids,\u201d to help balance the brains of kids with learning disorders, like Mallory.\n\u201cThe easiest way to get their brain to become coordinated is by making their body coordinated, so a large part of what we're doing is this sensory motor interaction, building their muscle tone, building their strength, building their body spatial awareness.\u201d\n\nThe program also incorporates what Melillo calls \u201cbionutritional\u201d guidelines to make sure children are getting the proper nutrition for optimal learning.\n\u201cWe tried some medication therapies that ended up being really a nightmare for us, and making matters worse.\u201d\n\nMedication is often the first line of defense in conventional medicine for kids with ADD and ADHD, with doctors prescribing everything from stimulants to antipsychotics and even antidepressants to help control the symptoms.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not include any mention of costs. Typically taking a child out of the home to attend any kind of face-to-face training for learning differences can be expensive. The story does not give us any idea what visits to Brain Balance Achievement Centers cost, or how many visits a typical family would make.\u00a0According to a news story\u00a0written about the franchised national chain, a typical course of therapy cost about $6,000 in 2010.", "answer": 0}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There are no mentions of costs in the piece. Ordinarily, we expect to see some discussion of what the cost may be\u2013especially when Wall Street is closely watching the drug\u2019s progress. In this case, however, the story makes it abundantly clear that the results were lackluster and so this drug is unlikely to be on the marketplace anytime soon.", "answer": 2}, {"article": "\"We have been trying as doctors for centuries to find a treatment that actually reverses heart injury,\" Eduardo Marban, MD, PhD, tells WebMD.\nIf so, this could change the nature of medicine.\nIt's the first completed, controlled clinical trial showing that scarred heart tissue can be repaired.\nMarban, director of the Cedars-Sinai Heart Institute in Los Angeles, led the study.\nHe invented the \"cardiosphere\" culture technique used to create the stem cells and founded the company developing the treatment.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The treatment is too experimental, and there are no comparable treatments to allow for a meaningful discussion of costs.", "answer": 2}, {"article": "Asked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\nEveryone from plastic surgeons to your friendly snake oil salesman have been promising a ticket to eternal youth for some time, so the prospect of a prescription pill based on red wine that could trigger a longevity gene sounds too good to be true.\nAnd yet scientists have actually known for years of one surefire of doing that: stay hungry.\nYeasts are one thing, human beings are more complicated.\n\"Our goal is to prevent and forestall many of the diseases that strike us as we reach 50, 60, and 70.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not speculate on the cost of the drug, which could be substantial. If it\u2019s not too early to speculate about all the potential benefits of this drug (how we could all be taking it soon and how it could prevent the diseases of aging) then it\u2019s not too early to speculate about costs.\u00a0 ", "answer": 0}, {"article": "\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nAssessing 130 relevant publications in the literature, as well as interpreting their own continuing studies, the all-Penn team found that in addition to its safety and effectiveness in fighting certain types of breast cancer, early trials of palbociclib have shown promise of effectiveness in cases of lymphoma, sarcoma, and teratoma, tumors that while rare, often afflict younger patients.\nAlso, combining palbociclib with other anti-cancer agents is feasible, and early results in myeloma and some solid tumors have led to more definitive studies.\nIn both breast and other cancer trials, palbociclib has been shown to be safe with once-daily dosing, and its main adverse effect is reversible neutropenia, an abnormally low count of neutrophils, a type of white blood cell that helps fight infections.\nAnother phase 2 trial with 29 sarcoma patients treated with palbociclib showed a progression-free survival of 66 percent at 12 weeks.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release goes to some lengths in describing the quantitative and qualitative benefits of pairing palbociclib with other anti-cancer drugs, but offers not a word about costs. In this case, costs are significant. Pfizer has pegged palbociclib at $9,850 per month. Carrying an informal calculation forward puts the cost of the drug at about $40,000 per prolongation of survival for four months. The consequences of such pricing remain unclear owing to subsidies and discounts. But for many patients the costs are not covered by insurance and drugs may not be\u00a0accessible to all who need them. They also put a major strain on the entire health care system.", "answer": 0}, {"article": "Hot flashes, which mostly affect women transitioning to menopause and already in that phase of life, involve a sudden sensation of heat, sometimes accompanied by sweating or visible reddening of the skin.\nAnd right now, HRT is the only treatment approved by the U.S. Food and Drug Administration for cooling hot flashes.\nThat\u2019s important because it gets at quality of life, according to the researchers, led by Janet S. Carpenter of Indiana University in Indianapolis.\nRight now, no antidepressant is specifically approved to treat hot flashes.\nThose findings appear in a separate report in the journal Menopause.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does discuss how much Lexapro \u2013 the antidepressant mentioned in the article \u2013 costs.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe U.S. Food and Drug Administration today approved three new indications for Ilaris (canakinumab).\nThere are no previously approved therapies for TRAPS or HIDS/MKD.\nIlaris was previously approved for another periodic fever syndrome called Cryopyrin-Associated Periodic Syndromes (CAPS) and for active systemic juvenile idiopathic arthritis.\nIlaris can cause serious side effects, including increased risk of serious infections.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "FDA releases don\u2019t typically assess cost, but seeing as this treatment is already on the market, it would not have been much of an effort to include that information in the news release. One might assume that the costs of treating these rare diseases are substantial but the release gives no indication on cost, or whether the drug might be covered by insurance.\nAccording to one trusted source on average retail drug prices, llaris prescriptions cannot be filled at a typical pharmacy. Instead, the medicine is administered and distributed at a hospital or clinic. This suggests the drug may be very expensive.", "answer": 2}, {"article": "Another company, TrovaGene, has developed a DNA test using urine, which, according to Gabriele Cerrone, TrovaGene\u2019s co-founder and director, is 95 percent accurate at predicting boys at seven weeks, and 88 percent accurate at predicting girls.\n\u201cIndividuals need to be careful\u201d to ensure that companies use rigorous laboratory procedures and support accuracy claims with data, she added.\n\u201cIt\u2019s very important to educate health care providers that pregnant women are buying these tests.\u201d\n\nAnother type of test not studied by the researchers has become popular because it is cheaper and can be done at home.\nRebecca Griffin, a founder of the biggest seller, Intelligender, said two independent studies found it 90 percent accurate at 10 weeks.\nLab fees and shipping costs, which vary, bring the total expense to $265 to $330.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story quotes one price estimate of about $250 for the testing. We would have liked more detail about whether new details on accuracy of the tests might change their status in the marketplace, or whether insurability status might change.", "answer": 1}, {"article": "\"The goal is to create cells that are missing or defective in people.\nAlthough the experiment involved mice, Melton and other researchers were optimistic that the approach would work in people.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\nMelton and other researchers cautioned that many years of research lay ahead to prove whether the development would translate into cures.\nResearchers in the field, who have become accustomed to rapid advances, said they, too, were surprised by the advance.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no cost estimate because there has not actually been a treatment developed yet that makes use of the approach described in the research.", "answer": 2}, {"article": "\"Whereas the typical developing kid will have an explosion of their language ability starting at about 12 months in both comprehension and production, kids in autism delay don't start comprehending or producing until later, and they don't ever have that kind of explosion.\nAnd when it is ready for prime time, it probably won't be applicable to all children with autism.\nBefore bringing it to clinics, researchers need to make sure this test isn't detecting other developmental delays such as dyslexia, he noted.\nBut another expert pointed out that the study is still extremely preliminary.\n\"If we could use this with other markers, we could probably identify people early on and, if we could do that, we'd have a much better chance of helping to make sure that their language development is normal.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "At a minimum, the reporter could have found out what a typical fMRI scan costs for someone without insurance and for someone with basic insurance. It also could have found out what one of the machines costs a hospital to purchase and, perhaps, how many are acutally in use nationwide.", "answer": 0}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This was a strong point of the piece. The story contrasts the much higher cost of eBx relative to standard skin cancer treatments, referencing an editorial in the journal JAMA Dermatology. \u00a0The cost issue is situated high in the story, and the text then devotes space later in the story to a more detailed explanation.", "answer": 1}, {"article": "In one study, the number of daily hot flashes experienced by postmenopausal women taking 1,800 milligrams of the drug per day declined from around 10 to around 2.\nThe study was presented in Chicago at the annual meeting of the North American Menopause Society (NAMS).\nBut side effects, including dizziness and daytime sleepiness, were commonly reported by users.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\nAbout 60% of women who took the experimental drug in one study reported side effects, compared to about 50% of women taking placebo pills.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "", "answer": 0}, {"article": "\"We talk with older folks and many say, 'I can't exercise, but maybe I can become more physically active.'\n(Canes were OK.)\n\nHalf of the participants got a health education program involving regular in-person sessions and some stretching exercises, while the other group was told to aim for 150 minutes of aerobic activity as well as strength, flexibility and balance training both at the study's facilities and at home.\nThe exercise program pretty closely followed the government's recommendations for all adults, including older ones: 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise per week, plus two strength sessions that hit all the major muscle groups.\nWalking Fends Off Loss Of Mobility, And It's Not Too Late To Start\n\nPeople who have reached their later years may think it's primarily a time to relax, not to increase their physical activity.\n\" Study participants were advised to \"start low and go slow,\" and some were even able to get rid of their canes after six months of exercise, which Gill says they found particularly rewarding.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rate this\u00a0category as non-applicable since the thrust of the story and the project it reports about is for elderly persons to adopt a routine of physical activity, the core of which is walking, which costs nothing. Certainly some costs are possible, say if for example a gym membership was desired, but neither the study or the story recommended that.\u00a0 Simple walking seemed to net ample positive results.", "answer": 2}, {"article": "Dominic Gessler lifts two squirming mice from their cages.\nAAVs are not quite as efficient as adenoviruses at getting genes into human cells, but they are much safer: The human immune system barely notices the virus\u2019s outer coat or \u201cdress,\u201d as Gao calls it.\nAnd attuned to the multibillion-dollar potential of this new class of drugs, large pharmaceutical companies including Novartis, Shire, AstraZeneca and GSK are joining the fray.\nScientists now argue it is our best, and perhaps only, chance at curing many diseases of the brain.\nGao estimates it will require $10 million to $12 million to launch the first human clinical trials\u2014but the potential profits are already attracting biotech attention.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "While some therapeutic strategies appear to have been approved in China and Europe, according to the story, none has\u00a0been approved in the Unites States, suggesting that cost information isn\u2019t yet relevant. But the story does indicate how expensive these therapies might be, by\u00a0mentioning\u00a0a breathtaking bit of pricing by one European company: $1.4 million per injection.\nThis is enough to rate as Satisfactory, though the story could have done more to help patients\u00a0understand what pricing might look like for gene therapies, which is surely on the minds of the venture capitalists funding the research.", "answer": 1}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article omits mention of costs, an important public health issue.\u00a0A flu shot costs about $11, whereas FluMist costs about $20.\u00a0Even though equally effective in preventing the onset of flu, FluMist is less efficient than the flu shot.\u00a0", "answer": 0}, {"article": "\u201cIt\u2019s quite amazing,\u201d she said.\nThe women who took the 10-week stress-management class shortly after surgery reported feeling better and having fewer depressive symptoms such as anxiety than those who took a one-day, breast-cancer education session.\nStagl doesn\u2019t know whether the women are still using the techniques they were taught \u2014 which include mindfulness, deep breathing, visual imagery, cognitive behavioral therapy, and learning how to ask for help from friends and family.\nSo Stagl, now a clinical fellow at Massachusetts General Hospital, helped study a University of Miami program that taught 240 breast-cancer patients relaxation techniques and coping strategies.\n(Stagl and her colleagues tracked down 100 of the original participants; another 30 had died; and 110 couldn\u2019t be found or didn\u2019t want to participate.)\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not address costs at all. It is not clear whether the type of group-based\u00a0cognitive-behavioral stress management program\u00a0discussed in the study is free for most patients, whether it is likely to be covered by insurance, or whether it would require a significant out-of-pocket expense for breast cancer patients.", "answer": 0}, {"article": "Women are also more likely to experience a condition known as left bundle branch block, a pattern of disorganized electrical impulses that responds well when the left side of the heart is treated with a pacemaker.\n\u201cThis was far greater than expected.\nThe device also included a defibrillator used to shock dangerous heart beats back into normal rhythm.\n\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\n\u201cWe found there was a dramatic reduction not only in heart failure events, but a very dramatic reduction in death from any cause,\u201d Moss said in a telephone interview.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of costs. These things are not cheap.", "answer": 0}, {"article": "For more information, visit the Institute's website at http://www.nichd.nih.gov.\nOverall, these findings suggest that starting steroid treatment promptly \u2014 even if the likelihood of completion is low \u2014 is beneficial when extremely premature birth is imminent.\nResearchers evaluated 6,121 extremely premature infants who had been born between 22 and 27 weeks of pregnancy at sites in NICHD\u2019s Neonatal Research Network.\nThe new study, supported by NIH\u2019s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), provides strong evidence that even a partial course can have some benefit.\nHowever, because completing the entire course takes at least 48 hours, health care providers may opt not to begin treatment when premature delivery is imminent.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The two antenatal steroids (ANS) used in this study included betamethasone and dexamethasone, but their costs were never mentioned.\nA complete course of ANS was defined as 2 intramuscular doses of betamethasone administered 24 hours apart or 4 doses of dexamethasone administered 12 hours apart. According to drugs.com, 500 mL of dexamethasone costs $23.94.\nOur online search didn\u2019t uncover any price estimates for liquid Betamethasone. Drugs.com only lists topical Betamethasone prices.\nWe always like to see a ballpark range of costs in news releases, so consumers can estimate their therapy costs. Since costs are not discussed in the news release, we give it a Not Satisfactory rating here.\nIt\u2019s worth noting here that the actual costs of the steroids pale in comparison to the cost of the overall treatment of these infants. \u00a0If the partial treatment is even\u00a0partially effective, that could lower future medical care costs.", "answer": 0}, {"article": ".\nPatients included in the trials were still having flare-ups despite a year of a standard treatment known as \"triple inhaled therapy\" that includes bronchodilators and glucocorticoids.\nThe 300-milligram dose did not provide an advantage over the lower dose.\nThe safety profile of mepolizumab did not differ from placebo in either trial.\nThe METREO results narrowly missed statistical significance.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the costs of the drug mepolizumab in the news release. An online search reveals that the price for the drug can run from $2,800 to $4,200 per vial (a one month\u2019s supply). Given that the drug appears effective only with some COPD patients, and its considerable price, readers would benefit from having this information, as well as perhaps the costs of standard therapies for COPD (triple inhalers and corticosteroids) which might still be needed by these patients.", "answer": 0}, {"article": "\u2022 Retrograde menstrual flow: During a period, when a woman is shedding her uterine lining, some of that tissue can flow through her fallopian tubes and into her pelvis, which researchers think may cause endometriosis.\nThat\u2019s not to mention cost: The drug\u2019s price is listed at $850 per month.\nDoctors aren\u2019t sure why some women get it\n\nAdding to the mystery around endometriosis: No one knows exactly what causes it, but doctors have some theories.\nSoon, it seems, women like Dunham with endometriosis pain will have a new option for relief.\nWe have no idea about the long-term effects of taking the drug because there are no trials lasting for longer than a year, or how it stacks up against other painkillers (since the trials only compared it to placebo).\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does a good job of describing the monthly cost ($850) for women who do not have health insurance. The inference is that insurers will cover the cost for others.", "answer": 1}, {"article": "About the Alzheimer's Research and Prevention Foundation\n\nThe Alzheimer's Research and Prevention Foundation is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\nThe full text of \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\" can be accessed at http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142766.\nKhalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\nTUCSON, Ariz., July 15, 2015 /PRNewswire/ -- Meditation and spiritual fitness are key components in reducing the risk of Alzheimer's disease according to a new article, \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\", published in an early online version of the Journal of Alzheimer's Disease 48(1).\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The Alzheimer\u2019s Research and Prevention Foundation states that the yoga technique is \u201caffordable\u201d in the news release. That\u2019s a step toward satisfying this criterion, but it\u2019s not clear whether the Foundation\u2019s definition of \u201caffordable\u201d is the same as readers\u2019 definition. Some numbers would have helped here. The Foundation\u2019s website provides instructions online on how to practice Kirtan Kriya yoga in six steps, and provides a link on how to order an accompanying CD for $20. Including a brief reference to that info in the release would have earned it a Satisfactory rating.", "answer": 0}, {"article": "Harder\u2019s PSA was 9.\nAn MRI can also help determine how aggressive a tumor is, Yu said, and indicates if the tumor extends outside of the prostate and involves other areas \u2014 all information that helps urologists and radiation oncologists determine the best course of treatment.\nAccording to the Center for Cancer Research study, MRI targeted biopsies detect 17 percent fewer low-risk tumors.\nIn addition to enhancing detection of prostate cancer, magnetic resonance technology also enhances the biopsy process with a procedure called magnetic resonance/ultrasound fusion biopsy.\nHe ends up diagnosed with cancer only after the tumor has spread to his bone or lymph nodes years later.\u201d\n\nMagnetic resonance imaging and targeted biopsy for the prostate have provided relief for patients like Harder who have not been able to get an accurate diagnosis.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "MRIs cost significantly more than ultrasounds, but that fact isn\u2019t mentioned. According to a story in the Wall Street Journal, an MRI can cost from $600 to more than $2,000, although Medicare and many private insurers typically cover some or all of that cost. Cost is all the more significant if, as VCU\u2019s director of oncologic and prostate imaging speculates in the news release, MRIs are eventually used like mammograms, with men getting baseline MRIs followed by repeated periodic scans if warranted by bloodwork and family history.\nSome mention of cost, relative cost or cost-effectiveness was warranted.", "answer": 0}, {"article": "\"We know that art therapy can work, music therapy can work.\nThe apps were freely available on iTunes and varied greatly in their cognitive complexity--from an app that displayed puppy photos to one that featured Sudoku puzzles.\nResearchers loaded a menu of 70 apps onto the tablets for the study.\nThe tablet, however, gives you the option of switching from one app to another easily, modifying the therapy seamlessly to suit the individual.\nHe and his medical support team also started using a translation app so that staff could ask him simple questions in Romanian, facilitating increased interaction.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release doesn\u2019t mention the price of the computer tablet used. It does note that the apps used were free to download on iTunes.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this drug is not yet available, we can understand that cost information was not included. But since the story points out that Merck is acquiring boceprevir for $41.1 billion, couldn\u2019t it at least have mentioned the\u00a0 high cost of current hepatitis C treatment, as well as the high cost of its complications?", "answer": 2}, {"article": "Swaminath noted that one study published in 2012 found that \"colonoscopy reduced the risk of death from colon cancer by 53 percent, by removing polyps.\nNow, researchers say a special scoring system might point to those people at highest risk for colon cancer, who may need the test the most.\n\"While high-risk patients may ultimately require a screening colonoscopy, many average- and low-risk patients could undergo less invasive screening procedures.\nHe believes that the scoring system \"was only modestly able to separate people within the risk groups.\"\nOne expert said more efforts are needed to get people to undergo colonoscopy, which is currently recommended once every 10 years beginning at age 50.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The question of cost is cited in the final line of the story, which suggests that the scoring system can \u201caddress escalating health care cost issues.\u201d But we didn\u2019t think that was specific enough to warrant a Satisfactory score. The story doesn\u2019t clue readers in to the fact that the financial burden can be measured in billions of dollars \u2014 a single screening test recommended for millions of Americans can cost thousands of dollars apiece. The other cost issue specific to this test is that it takes valuable time for providers to retrieve a reputable risk calculator when sitting with a patient and enter in the specific data points, including in this case waist circumference, which clinicians often do not measure as a \u2018vital sign\u2019 per se.", "answer": 0}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\nAdverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\nThe most common adverse events reported during the study included pain or burning with urination, blood in the urine, pelvic pain, urgent need to urinate, and the inability to control urine because of an urgent need to urinate.\nData from clinical trials showed that patients receiving UroLift implants reported rapid symptomatic improvement, improved urinary flow rates, and sustained sexual function.\nMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the costs of the procedure or the patented system used, nor of the downstream costs associated with recovery from the procedure. There was also no data on how long patients were followed and how many required a repeat intervention\u2013either repeat UroLift or other invasive treatment. This outcome has implications for both costs and effectiveness.", "answer": 0}, {"article": "His own previous research indicates that cannabis was used as early as 1800 B.C.\nShe was not involved in the new study.\nOn the need for more scientific research, all these experts agree.\n\"So, sadly, not a home run for most patients but another tool in our treatment regimen.\"\nHowever, there was a downside.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was not a discussion of costs for this intervention\u2013this was the weak spot in the story.", "answer": 0}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nA better option, he says, might be blood samples, which tend to contain greater numbers of the genetic fragments.\nA reliable test would help overcome a major obstacle in assessing and treating concussions, which affect more than one million children and adolescents in the U.S. each year.\nA reliable lab test would help ensure that children who have a head injury don't go back to school, or to the soccer field, before their brain has healed, Bhomia says.\nHicks and a team of researchers have been looking for an objective test that might help.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although this research is in early stages and it could be argued that it is too early to insist on a discussion of cost, the eventual price of this test will determine whether it would be used widely or not. For example, if it cost only a few dollars, it might be widely used by pediatricians (assuming it really works), but if it cost hundreds of dollars, it might not be used. The story should have at least tried to include some sort of ballpark cost estimate in order to tell the audience whether this sort of test would be practical.", "answer": 0}, {"article": "He is a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia.\nBut he noted that more research is needed because some patients remained in pain no matter what treatment they received.\nThe study results suggest acupuncture would be especially beneficial for patients who can't use standard pain-relieving drugs because of other medical conditions, Cohen added.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\nMONDAY, June 19, 2017 (HealthDay News) -- Acupuncture is a safe and effective alternative to pain medications for some emergency room patients, a new study reports.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no mention of the cost of acupuncture treatments in the story, nor was there any comparison between such costs and the costs for standard analgesic drugs that might be administered in an emergency department.\nA provider trained in acupuncture would need to be available at the time the patient needed assistance. If acupuncture increased time in the ED, that would add cost and reduce capacity for other patients. These are important considerations (as cost drivers) in a fast-paced environment.", "answer": 0}, {"article": "For more on childhood obesity, visit the U.S. Centers for Disease Control and Prevention.\nMONDAY, Jan. 12, 2015 (HealthDay News) -- School readiness isn't the only benefit young children can gain from Head Start.\nWhether those children were in another preschool program wasn't stated.\nThe program is designed to build stable family relationships, improve children's physical and emotional well-being and develop strong learning skills.\nHealth benefits, including weight loss, seem to be a byproduct of the program, said Dr. David Katz, director of the Yale University Prevention Research Center.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story states early in the article that the Head Start Program is free to impoverished children ages 3-5.", "answer": 1}, {"article": "Lee believes ibuprofen strips could be useful for sports participants, helping alleviate conditions such as tendonitis, and repetitive strain injuries.\nWe\u2019re controlling the dosage and we\u2019re keeping it there for a prolonged period of time.\u201d\n\nThe patches could help treat conditions like chronic back pain, neuralgia and arthritis without the need to take potentially damaging doses of the drug orally.\nWe\u2019ve tested them in our polymers with very good results, we\u2019ve been able to get increased loadings of drugs in the polymer and we\u2019ve shown almost across the board that we can get a steady release rate of that drug from the polymer as well.\u201d\n\nThe team says TEPI patches could go on sale within three years, and Medherant is working with some large, unnamed, pharmaceutical companies to get them ready for market.\n\u201cWhat we do is dissolve the active ibuprofen, for example, into the adhesive so we can have quite a high loading - so up to 30 percent of the adhesive will be the ibuprofen,\u201d said Haddleton.\n\u201cOne of the interesting areas that we plan to explore in partnership with large companies is actually using our platform technology to include other drugs that previously maybe haven\u2019t been suitable for topical or transdermal delivery - or drugs which may have not got through the regulatory filings because, for instance, they might have caused stomach irritation or other side effects when taken orally,\u201d said Lee.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We\u2019ll rate this\u00a0N/A since the patches are still in development for the consumer market. Having said that, we should point out that generic ibuprofen is very inexpensive. \u00a0It is very likely that the TEPI system will cost the consumer much more.", "answer": 2}, {"article": "A tiny but promising study suggests that a medicine used for immune disorders may offer long-term benefits to Alzheimer's patients\u2014a result likely to spur demand for the treatment even though it is in limited supply and isn't approved for the memory-debilitating disease.\n\nThe treatment, intravenous immunoglobulin therapy, or IVIG, is made from the blood plasma of healthy young adults. Since 2004 it had shown early promise for Alzheimer's, which afflicts some five million Americans.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story explained that the cost can be more than $50K/year.", "answer": 1}, {"article": "Some people (about 1 percent of whites; fewer of minorities) lack both copies of the CCR5 gene and are naturally resistant to HIV.\nThere are a lot of people out there with hopes and dreams around the C-word,\" so caution is needed.\nThe research was only meant to show that, so far, it seems feasible and safe.\n- What might this cost?\n- How long will the modified cells last?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We like this story\u2019s approach.\u00a0 The story could have easily stated that it\u2019s just too early to know \u2013 end of story.\u00a0 Instead, it stated:", "answer": 1}, {"article": "Professor Babaeva said: \"Our findings suggest that the decreased rheumatoid arthritis disease activity with the combination of anticytokines translates into decreased cardiovascular risk.\nTherefore, decreasing disease activity may also reduce cardiovascular risk by slowing down or halting these processes.\"\nThe current study investigated the impact of the combination of drugs on cardiovascular events.\ncan improve the efficacy of standard rheumatoid arthritis therapy and decrease cardiovascular risk,\" said Professor Babaeva.\nWe recommend this new approach for preventing cardiovascular events in patients with moderate disease activity who are not receiving the standard biologics and who do not have severe complications.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "No mention of costs, whatsoever. This may be a lost learning opportunity because these drugs are not only very expensive, but are also at the ends of their patent lives and hence generic companies are making cheaper biosimilars.", "answer": 0}, {"article": "Several companies, including one owned by Koniver, make herbal combinations.\nIn fact, for nearly all alternative practices there are no large-scale studies saying if they work or not.\nGiven these two rejections, it could be a while before another pharmaceutical company decides to sink money into developing a new drug for women with sexual problems.\nBut in the absence of a drug to help women with sexual problems, here's what's recommended by some practitioners.\nShocked and not quite sure what to do, she turned to medical doctors, and found there wasn't much they could offer, as there's no prescription medicine like Viagra to help a woman when her sex life gets stuck.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No information about costs here \u2014 significant considering that the therapies discussed have very little\u00a0evidence to show that they work and will be paid for out of pocket. ", "answer": 0}, {"article": "While skeptics may question the idea of using psychedelics as treatment for psychological distress, Hendricks emphasizes that he does not advocate for rampant recreational use of psychedelics, or widespread legalization.\nPerhaps this study will be a turning point in how our culture regards psychedelics and mental health.\nThe UAB isn't the first study to flirt with this idea.\nIt turns out contemporary science may back these ancient claims.\nA lack of resources and funding is a hindrance to continuing studies, however, as psychedelics are still classified as schedule 1 narcotics in the U.S. and criminal offenses accompany their possession.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No costs were cited, perhaps because the drugs are not legally available in the United States. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "had lower HDL-cholesterol, lower income, and less education,\u201d in comparison to participants who did not consume red chili peppers.\nLike spicy foods?\nIf so, science has some good news for you: Eating hot chili peppers may help you live longer.\nThe research is observational, so no cause and effect relationship can be established.\nBut experts caution that this doesn\u2019t mean everyone should pile on the spices at dinner time to improve their health and increase their longevity.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable. The intervention was an easily available and inexpensive food.", "answer": 2}, {"article": "She said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nThe study was funded by Takeda Pharmaceutical (which is developing the drug), and appears online Feb. 26 in The Lancet.\nOther diabetes experts had mixed views on the new findings.\nHowever, like Wissner-Greene, Sood said that \"further investigation is warranted, especially including [heart disease] patients.\"\nDr. Minisha Sood, endocrinologist at Lenox Hill Hospital in New York City stressed that, \"given the rising global incidence of type 2 diabetes, the medical community is eagerly awaiting the development of novel agents to add to our existing armamentarium of anti-diabetic agents.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It\u2019s too early to discuss costs for this specific drug, although some mention of the costs of competing drugs would have been helpful.", "answer": 2}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\n\"We have identified a cardiac troponin concentration (less than 5 nanograms per deciliter; <5 ng/L) below which patients are at very low risk of heart attack either during the admission or in the ensuing 30 days.\nUntil now, whether new high-sensitivity cardiac troponin tests could identify very low-risk patients who may be suitable for immediate and safe discharge from the emergency department was unknown.\nThis study shows that low plasma cardiac troponin concentrations at presentation identify up to two-thirds of patients who are at very low risk of heart attack and could be safely discharged from the Emergency Department.\nThe test used in this study is more sensitive than the standard version and can detect far lower levels of troponin in the blood.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release makes repeated reference to claims by the study\u2019s authors of substantial savings to the health care system, but no quantitative data are included. More significantly, there is no information presented about the cost of the high-sensitivity test or comparison to current per-patient cost for evaluating acute coronary syndrome in the British health care system. At a minimum, one would want to know the cost of this new test compared to standard troponin tests. Further work would be needed to assess the relative downstream costs associated with this new test.", "answer": 0}, {"article": "\"Oh, absolutely!\"\nTo put the difference in perspective, the avocado diet decreased LDL cholesterol about 14 milligrams per deciliter of blood.\n\"I was surprised to see the added benefit [of the avocado],\" Penny Kris-Etherton, a nutrition scientist at Penn State and the lead author of the study, tells us.\"\nNew research finds that eating an avocado per day, as part of an overall diet rich in healthy fats, may help cut the bad kind cholesterol, known as LDL.\nAnd given the reduction in funds available for research, it's become increasingly common for researchers to carry out these kinds of industry-supported studies.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Avocados are relatively expensive \u2014 a fact pointed out by several competing stories that covered this study, but not this story. Eating one per day regularly could cost in the ballpark of $30 per month, which may be out of reach for some people.", "answer": 0}, {"article": "Glaucoma is a leading cause of blindness.\nBut they added that blood pressure and other factors that can contribute to vessel size would need to be considered.\nThe study appears in the latest issue of the journal Ophthalmology.\nEarly detection is key, but without regular eye exams, most people don\u2019t know they have a problem, says ophthalmologist Andrew Iwach, MD.\nIn the study, researchers were able to predict who was at increased risk of developing the eye disease with some accuracy by measuring blood vessel thickness in the retinas of study participants using a computer-based imaging tool.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story didn\u2019t include anything about costs.\nWhat will it cost to use the \u201ccomputer-based imaging tool\u201d described in the story?\u00a0 We\u2019re not told. There is no information on the cost of expanding the use of retinal photographs to a wider population.", "answer": 0}, {"article": "The hope is that our positive surgical experience will help pave the way for future research into DBS and Alzheimer's,\" says Dr. Ponce.\nWhile the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\nThe ADvance Trial, using a device from Functional Neuromodulation, Inc., is aimed at evaluating the safety, efficacy and tolerability of DBS in this patient population.\nDuring the trial, 42 patients with mild Alzheimer's disease underwent the surgical procedure and were closely monitored for adverse effects.\nDr. Ponce adds that the next step is evaluating the efficacy and longer-term safety of the treatment, which will not be known until the last patient completes the two-year evaluation later this year.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no discussion of the cost of this procedure or the maintenance costs of the device. These numbers should be well-known as the device is currently used in Parkinson\u2019s patients and others. An article published in WebMD in 2011 estimated the surgery runs between $30,000 and $50,000.", "answer": 0}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not cite the cost of the patch sold in Europe, which could be a marker for possible pricing in the U.S.\nIn a story that discusses the competitive commercial environment of the treatment\u2019s development, this is a serious shortcoming.\u00a0 ", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Because the story discusses the potential harms of oophorectomy, the cost criterion is not necessarily applicable in this case.", "answer": 2}, {"article": "Hyaluronic acid is a lubricating fluid that is naturally found in the knee, but degenerates over time in people with osteoarthritis.\n\"We have an epidemic of osteoarthritis of the knee and we have limited treatment options,\" says Dr. Richmond, who was not affiliated with the analysis but who reviewed the same data it was based on.\nThe authors of the study discourage patients from getting this treatment.\n\"This is most effective in relatively younger patients, 40 to 50 to 60 year olds, and...in people with mild to moderate forms of the disease,\" says Richmond.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No discussion of cost.\u00a0 One estimate we quickly found online put the cost at about $1500 per knee \u2013 perhaps without insurance coverage.", "answer": 0}, {"article": "Among the 620 adults (average age, 71 years; 74 percent women) who were randomized, 96 percent completed the study.\nThe researchers add that close contact casting may be an appropriate treatment for older adults with unstable ankle fracture.\nAlthough close contact casting may be unfamiliar to some orthopedic surgeons, it can avoid surgery for older patients with ankle fractures, yet result in equivalent functional outcomes.\nFurther studies are needed to help identify which patients will not benefit from casting.\nCasting required less operating room time compared with surgery.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release notes that casting instead of surgery as an initial treatment would result in \u201creduced intervention costs\u201d but that\u2019s not very helpful if you\u2019re unsure of the base cost of surgery.\nEstimates of a cost differential would have been helpful. Close contact casting would be much cheaper than open surgery for these fractures.", "answer": 0}, {"article": "; Nirubol Tosakulwong; Kent Bailey, Ph.D.; Julie Fields, Ph.D.; Lynne Shuster, M.D.\nThe oral treatment was not associated with lower amyloid deposition.\nThe researchers used positron emission tomography, also known as a PET scan, to look for the brain amyloid deposits three years after the trial ended.\n\u201cThis study showed, for the first time, that the brain amyloid deposition \u2500 a hallmark of Alzheimer\u2019s disease \u2500 is reduced in newly postmenopausal women who received 17beta-Estradiol patch form of hormone therapy,\u201d says lead author Kejal Kantarci, M.D., a Mayo Clinic radiologist.\nThis study is funded by the Aurora Foundation to the Kronos Longevity Research Institute and NIH.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Costs for hormone therapy are readily available but they are not broached in this release.", "answer": 0}, {"article": "People with insomnia may have one or more sleep problems, including difficulty falling asleep, trouble staying asleep and difficulty getting back to sleep after waking in the night.\nOn average, it took patients 21.6 fewer minutes to fall asleep with the 40 mg dose of MK-4305 than a placebo on night one, Merck said.\nThe drug, MK-4305, helped patients sleep for a larger percentage of eight hours spent in bed at one night and at the end of four weeks of treatment, Merck said.\nHe said the 80 mg dose was likely more than most people need.\nThe drug also demonstrated superiority to placebo in the time it took to fall asleep and time spent awake after initially falling asleep, Merck said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "No. And this really is a shame because there are a lot of sleep aids on the market. Given the doseage, there could have been a way to talk about what drug this might replace or compete with and how much that drug costs, at a minimum.", "answer": 0}, {"article": "PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\nEsophageal cancer is the seventh most commonly diagnosed cancer in the world, the company said.\nMerck said trial results would be presented at an upcoming medical meeting.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs were not mentioned and that\u2019s a big omission when you\u2019re discussing Keytruda. Drugs in this class of checkpoint inhibitors are estimated to cost about $150,000 a year.", "answer": 0}, {"article": "Elisabetta Politi, nutrition director of the Duke Diet and Fitness Center at Duke University, said, \"We advocate that people eat nuts, including walnuts, because they are high in healthy fat, low in carbohydrates and a good source of protein.\"\nWalnuts have long been touted as a healthy, whole food, but new research just upped the homely nut's reputation another notch.\nThey're rich in fiber, folic acid, and potassium.\n\"Try a serving in a snack bag.\n\"\"It's encouraging to see that eating walnuts may benefit this particular population.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Since this is a study of older adults\u2013who are often on fixed incomes\u2013an estimate of cost would have made the story stronger. But because walnuts aren\u2019t notably expensive compared to other nuts, we\u2019ll give this a pass.", "answer": 2}, {"article": "(That\u2019s a high dose; a 3 oz.\nOne thing that has been less clear is what role fish oil plays in people who have already had a heart attack.\nStudies have shown that people in parts of the world who eat more fish have lower rates of heart disease, and fewer heart attacks (though the same can\u2019t necessarily be true of those who take supplements\u2014see this piece \u201cFish Oil Is Hugely Popular\u2014But Should You Take It?\nMany heart doctor will tell you that one of the best ways to keep your heart healthy is to include more healthy oils, such as omega-3 fatty acids found in fish, in your diet.\nCan omega-3 fat provide similar benefit?\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs of the intervention are not disclosed. A casual reading of the news article may lead one to believe that over-the-counter fish oil was used in the treatment arm of the study. However, our\u00a0own careful reading of the original study reveals that GlaxoSmithKline (Research Triangle Park, NC) provided both the fish oil and placebo pills. (The study was solely funded by the\u00a0National Institutes of Health.)\nA curious reader might ask what is the cost discrepancy between the fish oil by GlaxoSmithKline and a standard over-the-counter fish oil product, too.", "answer": 0}, {"article": "It makes the virus particle fall apart,\" he said.\nIf those studies prove to be successful, human testing could be next.\n(CNN) Finding ways to fight the flu just got a tad more ribbeting -- that is, if you ask some researchers who have turned their attention to frogs.\nIt doesn't touch H3.\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "This story describes basic research that has not even reached the human clinical test stage. Because it makes this clear and adds lots of backstopping so as to prevent readers from wondering if this is an available treatment, we\u2019ll rate this N/A.", "answer": 2}, {"article": "The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues\n\nThe American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world.\n\"While we can operate on ears later in the patient's life, waiting not only increases the surgery's difficulty and expense, but may expose the child to teasing, bullying, and loss of self-esteem,\" comments Editor-in-Chief Rod J. Rohrich, MD, in a featured video on the Plastic and Reconstructive Surgery website.\nWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach--including a standardized approach to treatment and assessment of the results.\nBut lack of awareness of this nonsurgical alternative is a key limiting factor.\nThey also point out that EarWell is highly successful in the treatment of prominent ears--a condition that commonly goes unnoticed by parents and pediatricians, but is likely to get worse as the child grows.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release does not address cost at all, which is particularly unusual given that the release focuses on the use of a product that is already on the market. Given that online cost estimates for the EarWell system range from $2,500 to $4,500 per ear, this is a significant oversight.", "answer": 0}, {"article": "Both Florbetapir F 18 and florbetaben help diagnose Alzheimer's by sticking to beta amyloid clumps and emitting radioactivity, which can then be picked up by a PET scan.\nOnce that happens, physicians, researchers and insurers will need to figure out who should get the test and at what cost, and who will pay.\nFor now, says Weiner, there is \"no consensus\" on which patients should get the costly new PET scans that use Amyvid, and large insurers such as Medicare and Medicaid have not made decisions about coverage for such tests.\nAnd some patients may question whether they would want to know that the source of their mental troubles is Alzheimer's disease, said Weiner.\nThe \"real game-changer,\" he says, will be when one of the many experimental therapies under study for Alzheimer's disease succeeds in blocking or reversing its progress.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story calls the test \u201ccostly\u201d but does not quantify it. The cost of the agent itself, the associated PET scanning, and the interpretation of the test are not mentioned. The story does state that the test is not covered by Medicare or major insurers at this time, but readers have no idea what they would be on the hook for if they decide to pay for the test out of pocket.", "answer": 0}, {"article": "\u201cBut it has hit the lay press,\u201d she said.\nUntil more is known, physicians are hesitant to participate.\nNow, in the first study of its kind, researchers on Monday confirmed that a mother\u2019s beneficial microbes can be transferred, at least partially, from her vagina to her baby after a C-section.\n\u201cThe study is extremely important,\u201d said Dr. Jack Gilbert, a microbial ecologist at Argonne National Laboratory who did not take part in the work.\nFor the first few days, ambient skin bacteria from the delivery room predominated in the mouths and on the skin of C-section babies who were not swabbed, Dr. Dominguez-Bello said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not discuss the costs associated with inoculation. However, it\u2019s implied that vaginal microbial transfer is very inexpensive (it only requires a piece of gauze, saline, and a sterile bottle \u2013 all standard hospital supplies) so we won\u2019t ding the story for this omission. With that being said, there is a tacit assumption in the article that the transfer of bacteria from the mother\u2019s vaginal fluids to the newborn is always in the best interest of the newborn. Clearly this is not the case as we will articulate later. If there is a risk of the transfer of less than desirable bacteria, it is reasonable to assume that bacterial screening of vaginal secretions might be undertaken (which would add cost). The transfer of pathogens to the newborn inducing infection would also have a cost. While it is beyond the scope of this report, we think that thinking about the potential downsides of a new intervention is in order.", "answer": 2}, {"article": "It will still grow shorter and slower than scalp hair,\u201d he said.\nOn average, a procedure involves 1,500 to 1,800 follicles and takes about eight hours, with breaks.\n\u201cIf you transplant leg hair on the head, it\u2019s not going to start acting like head hair.\nBut hair that comes from the back of the head is typically much coarser than the fine hair that grows in front.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The closest readers are given about any sense of costs is the amount of work involved. The story says \u201cOn average, a procedure involves 1,500 to 1,800 follicles and takes about eight hours, with breaks.\u201d Cosmetic surgeons don\u2019t work cheaply, and insurance is likely not to cover these procedures. All it would have required is one question to the surgeon, \u201cHow much does it cost to transplant 1,500 to 1,800 follicles\u201d?\n\u00a0", "answer": 0}, {"article": "Research has shown that giving statins to patients who already have Alzheimer's does not seem to help.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\nA patient calls you up and says \"I'm losing my memory a little, would you be tempted to put them on a statin, LaPook asked.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The segment does not indicate how much statins cost. They range from pennies to nearly $4 per pill.\u00a0 \nGiven the anchor\u2019s and reporter\u2019s questions about whether people should start taking statins now as a prophylactic despite conflicting research, the price should have been mentioned.\u00a0\n\u00a0", "answer": 0}, {"article": "Regions of the brain that typically contain accumulated tau protein include the temporal lobe, parietal lobe and occipital lobe, among others; grey matter in the cerebellum is thought to contain low or no tau in patients with Alzheimer's.\nThe authors report no other relevant potential conflict of interest.\nAn additional six older healthy controls were recruited for full-body scanning.\nThis study was funded by an F. Hoffmann-La Roche Ltd. contract to The Johns Hopkins University.\nThe study was divided into three parts.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Cost isn\u2019t discussed.", "answer": 0}, {"article": "Stroke is the single largest cause of adult disability and the third-largest cause of death in the developed world.\nRoger Bonomo, director of stroke care at Lenox Hill Hospital in New York, said another way to look at the implications of this trial would be as justification for treatment of post-stroke depression before it progresses.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\nThere were also more independent patients and depression was less common in the Prozac group than in the placebo group, and side effects of the drug were rare and mild, researchers said.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "It mentions that the drug is available generically and is generally inexpensive. It also discusses the economic impact of stroke, teeing up the potential downstream cost savings, in terms of disability care avoided, if the benefit of\u00a0fluoxetine in this setting proves to durable.", "answer": 1}, {"article": "Post-operative cognitive dysfunction (POCD), a condition mostly observed in older patients following surgery under general anesthesia, is characterized by impaired memory and concentration.\n\"Little is said about rehabilitation or ways of helping patients recover pre-operative cognitive function.\"\nBefore that, older patients were rarely subjected to major surgery, and significant research in this field has only been conducted for approximately 15-20 years.\nThe good news, according to a Brazilian study published by the journal PLoS One, is that two relatively simple measures can help to reduce the incidence of POCD: administering a small dose of the anti-inflammatory drug dexamethasone immediately before an operation and avoiding profound anesthesia during the operation.\nOne of the obstacles to reliable diagnosis and rehabilitation is a lack of practical and secure instruments for pre- and post-operative cognitive assessment.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release doesn\u2019t discuss cost at all, which is somewhat surprising given that dexamethasone has been on the market for many years with various clinical applications. It\u2019s not that dexamethasone is especially expensive (it isn\u2019t \u2014 though the cost isn\u2019t necessarily negligible), but that cost needs to be addressed. Readers are simply given no information about cost.", "answer": 0}, {"article": "Akins was optimistic.\nWhile the study findings indicate that there is a consistent signal present in circulating blood cells of children with spastic CP that remains from early childhood to the teenage years, the researchers say they need to further study samples from different age groups, including teenagers, toddlers, and infants from birth to 2 years.\nThe work represents a collaboration among researchers at Nemours, the University of Delaware (UD) and Genome Profiling LLC (GenPro for short).\nThe approach uses sophisticated machine learning techniques and algorithms to sort through hundreds of gigabytes of NGS data looking for these distinct DNA methylation patterns.\nIf successful, the researchers say the type of blood test in development also may be useful for other disorders, such as infant leukemia.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this proposed diagnostic approach anywhere in the release. The entire approach to the claims made in this release relies on next generation sequencing of blood samples which can run into hundreds and sometimes thousands of dollars. The research paper points out that the approach relies on the use of parallel computing facilities, a highly expensive capability for many medical centers.", "answer": 0}, {"article": "Dr Joanna Bowtell, head of Sport and Health Sciences at the University of Exeter, said: \"Our cognitive function tends to decline as we get older, but previous research has shown that cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\nThe research was carried out in association with the University of the West of England, and the concentrated blueberry juice (BlueberryActive) and some funding for the study was provided by CherryActive Ltd, which produces cherry, beetroot and blueberry products in concentrate and capsule form.\nDrinking concentrated blueberry juice improves brain function in older people, according to research by the University of Exeter.\nBlueberries are rich in flavonoids, which possess antioxidant and anti-inflammatory properties.\nOf the 26 healthy adults in the study, 12 were given concentrated blueberry juice - providing the equivalent of 230g of blueberries - once a day, while 14 received a placebo.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "There is no mention of the cost of this blueberry concentrate. According to the manufacturer\u2019s website, a 473ml bottle of BlueberryActive Concentrate sells for \u00a317.99 British pounds, or $21.85 in US dollars. Thirty blueberry capsules cost $13.35 in US dollars.", "answer": 0}, {"article": "They included sharing news about friends or relatives or plans for the day as a way to involve their spouse in day-to-day events; waiting patiently and keeping eye contact while spouses searched for words; and finding alternate ways to communicate \u2014 for example, singing songs together when attempts to engage the spouse in certain topics failed.\nThese patterns showed the caregivers applying what they\u2019d learned through coaching in creative ways, she said.\nFuture research might focus on interventions that could help diffuse these frustrations, the paper noted.\nThe caregiving spouses seemed to value their partners\u2019 efforts to communicate as much as or more than the actual content of their conversations.\n\u201cSome past research has involved a caregiver giving directions and seeing if his or her spouse [with Alzheimer\u2019s] can follow.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Costs are not discussed. In fairness, the use of the strategies revealed by this study really costs nothing, but there has to be some educational component to train caregiver spouses in their use, and such instruction would carry some cost. The story could have given us some idea of what might be entailed.", "answer": 0}, {"article": "\"I don't like to play my son's video games, but I keep telling myself to challenge myself,\" said Marsiske, 41.\nThe study did not indicate that mental training can hold off all cognitive decline permanently.\nThe researchers also showed that the benefits of the brain exercises extended well beyond the specific skills the volunteers learned.\nSherry L. Willis, the lead author of the study and a Pennsylvania State University professor of human development, said those who had the training also reported greater confidence in their ability to solve everyday problems, and this was especially true of the group that got the reasoning training.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story mentioned that 'Mental activities do not have to involve expensive toys\u2026\" there was no estimate of costs that might be associated with the types of mental activies described in the study nor how one might find someone trained in these interventions to work with.", "answer": 0}, {"article": "In the study of 35,016 older women with no history of breast cancer, those who reported currently taking fish oil supplements on a regular basis had a 32% reduced risk for developing invasive ductal breast cancer, compared with women who did not take fish oil supplements.\nExactly how fish oil may affect breast cancer risk is not fully understood, but it may be related to its strong anti-inflammatory properties.\n\"If you are taking fish oil now for other reasons, this is reassuring that it may have beneficial effects beside what you are taking it for,\" she says.\nMany people currently take fish oil supplements to decrease their risk for heart disease.\nThe new research is part of the Vitamins and Lifestyle (VITAL) study, which included data from women 50 to 76 years old from Washington state.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Not applicable.\u00a0 Not discussed, but it should be general knowledge that they\u2019re relatively inexpensive. ", "answer": 2}, {"article": "After doing it for so long, it's not hard to do.\"\nThe prevalence of diagnosed diabetes has more than doubled in three decades due in large part to an upsurge in obesity, the study states.\nThat means lifestyle changes were twice as effective as medicine in delaying or preventing diabetes.\nBenefits of intensive lifestyle changes were most pronounced in the elderly, with people 60 or older reducing the rate of developing type 2 diabetes by half.\nFor 10 years, researchers tracked 2,766 people nationwide with pre-diabetes -- a metabolic condition featuring slightly elevated blood-glucose levels that often serves as a precursor to type 2 diabetes.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The reporter misses an opportunity to say how much it costs to participate in a diabetes prevention program\u2013or to take metformin.\nA creative reporter could then have compared those costs to the costs of managing diabetes.\u00a0\nDuring a time when costs of health care are so much in the public\u2019s mind, people reporting on treatments should always probe the question of costs vs benefits. \u00a0 ", "answer": 0}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "As we noted in our review of TIME Magazine\u2019s story as well: Although there may not yet be any accurate prediction of the cost of the particular therapy described for this single patient, it is generally well established and well documented that immunotherapies\u2013particularly those that involve modifying a patient\u2019s own immune cells\u2013are many times more expensive than standard treatments, sometimes running to annualized costs in the hundreds of thousands of dollars. \u00a0This story\u00a0says nothing about this.", "answer": 0}, {"article": "Insulin helps glucose (sugar) enter cells to provide fuel for those cells.\nDr. Joel Zonszein, an endocrinologist from Montefiore Medical Center, in New York City, praised the study but said some questions still remain.\nThe researchers said larger and longer trials are needed to assess the hormone's therapeutic potential.\nBaker said it wasn't clear why this happened, but she suspects the body may be trying to compensate for an insulin shortage in the brain in people with memory problems.\nBaker said the researchers saw benefits in healthy adults and those with mild cognitive impairment who received GHRH.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost was never mentioned \u2013 a significant oversight since, as Reuters Health reported, a single shot may cost $700.", "answer": 0}, {"article": "To test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nThe findings were published online today in Pediatrics.\nAug. 16, 2010 -- A probiotic supplement may be an option for parents trying to soothe a colicky baby, according to a new study.\nAll the infants were diagnosed with colic, born full-term at a healthy gestational weight, had no history of gastrointestinal disorders, were breastfed, not formula fed, and did not receive any other probiotic supplements during the week prior to the study.\nThe infants' mothers were also advised to avoid cow's milk in their own diets during the study period.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not mention how much treatment with this probiotic costs. A month\u2019s supply costs about $40 according to one Internet retailer\u2013information that easily could have been included\u00a0in the piece. \u00a0", "answer": 0}, {"article": "The scientists, meanwhile, collected blood samples from the men several weeks before the race, as well as immediately before to the start, at the finish line and on select days afterward.\nAlcoholic beer happens to be drenched in polyphenols, too \u2014 \u201ceven more than nonalcoholic beer,\u201d Dr. Scherr said \u2014 but has the signal disadvantage of being alcoholic.\nJust how nonalcoholic beer eases the ravages of strenuous marathon training and racing is still being investigated.\nThese effects matter, said Dr. Johannes Scherr, lead author of the study, because if a marathon runner\u2019s body is less sore and inflamed after a race, and he doesn\u2019t develop the sniffles, he can recover and return to training more quickly than he otherwise might have been able to.\nRunning a marathon is, of course, punishing to the body, causing muscle soreness and inflammation.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Discussion of costs is relatively unimportant as most individuals would know how much beer costs.", "answer": 2}, {"article": "About CVS Health \n\nCVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health.\n\"In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.\"\n\"At CVS Health, we provide important home infusion services to patients through Coram, which is just one of the ways we are expanding our clinical delivery model and helping to move important health services to lower cost sites of care,\" added Alan Lotvin, MD, Executive Vice President, CVS Specialty.\nThe costs associated with home infusion were also consistently lower than services provided in a health care facility, with savings ranging between $1,928 and $2,974 per course of treatment.\n\"Our research shows that home infusion care is a promising model that is both cost- and clinically-effective and is overwhelmingly preferred by patients when intravenous therapy is required.\"\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The news release includes information about costs. We would have liked a little more context. The release states: \u201cThe costs associated with home infusion were also consistently lower than services provided in a health care facility, with savings ranging between $1,928 and $2,974 per course of treatment.\u201d\nWe need to know what percentage of savings that is per course of treatment. If the whole course costs $100,000, then saving $1,928 is a pretty small percentage. If the whole course is $10,000, than a savings of $1,928 looks more substantial.", "answer": 1}, {"article": "Also some fancier CT studies, involving multiple \"slices\" through the body in a single examination, can be replaced by simpler CT tests, conventional X-rays or tests such as ultrasound or MRI that don't involve radiation.\nTo cut down on unnecessarily high radiation doses, Thrall says, the College of Radiology is also developing an \"alarm\" system that will alert hospitals when their CT scan exceeds an acceptable dose.\nHe says at his institution, the Massachusetts General Hospital, doctors who order a CT scan or other imaging study must list the reason.\nA separate study in the journal documents needlessly high radiation exposures from CT scans at four San Francisco-area hospitals.\nThat will require hospitals to feed dose data to a central computer run by the radiology group.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not mention costs of CT scans, which are substantial. ", "answer": 0}, {"article": "Learn more about Parkinson's disease and its symptoms at the Parkinson's Disease Foundation.\nThe study had some limitations, the authors acknowledged.\nIt's thought these drugs may have potent anti-inflammatory effects, which could protect the brain.\nThere was a concern that statins could be harmful as they might lower the level of coenzyme Q10 in the blood.\nThe researchers can't say exactly how -- or even if -- statins reduce the risk of Parkinson's.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There is no discussion of costs in the story. At least a mention of the typical price for a statin would have been nice, given that they are lifelong drugs that add up to a considerable amount over time.", "answer": 0}, {"article": "Saturated fat has been thought to promote cardiovascular diseases by raising the \"bad\" LDL cholesterol in the blood.\n\"These results indicate that most healthy people probably tolerate a high intake of saturated fat well, as long as the fat quality is good and total energy intake is not too high.\n\"But the alleged health risks of eating good-quality fats have been greatly exaggerated.\nIt may be more important for public health to encourage reductions in processed flour-based products, highly processed fats and foods with added sugar,\" he says.\nThe researchers found strikingly similar health effects of diets based on either lowly processed carbohydrates or fats.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The release does not mention costs but we won\u2019t fault it for this. We rate this Not Applicable since it would be very difficult to estimate the cost of shifting eating patterns that incorporate more foods laden with saturated fats.", "answer": 2}, {"article": "The results have not previously been published or presented.\nThere is also a dramatic price difference between the two diagnostic tests.\nAccording to Dr. Ruhwald, a TST costs about $2; an IGRA is 20 to 40 times more expensive depending on setting.\nThe field-friendliness and high specificity offered by the C-Tb test could allow for improved targeted treatment of M. tuberculosis-infected persons in also in resource-constrained settings, where IGRAs are too complicated to implement.\nThe cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This release provides a very good discussion of costs, stating, \u201cThere is also a dramatic price difference between the two diagnostic tests. According to Dr. Ruhwald, a TST costs about $2; an IGRA is 20 to 40 times more expensive depending on setting.\u201d This gives readers a clear idea of the fiscal advantage of using the new test.", "answer": 1}, {"article": "Botox injections are also used, often in cases where the medicine does not work.\n\u201cThese are both effective treatments,\u201d said the lead author, Dr. Anthony G. Visco, an associate professor of obstetrics and gynecology at Duke.\nThe scientists, writing online on Oct. 4 in The New England Journal of Medicine, found that both treatments significantly reduced incontinence episodes.\nThe medicine has to be taken daily, while Botox is given in a single injection that is effective for about 6 to 12 months.\nNow a placebo-controlled study has found that the treatments are equally useful in reducing the frequency of episodes of incontinence, but vary in side effects and long-term effectiveness.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not compare the prices between a six-month supply of anticholinergic drugs and a single botox injection.", "answer": 0}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not addressed, which is unacceptable given that both drugs are already on the market. And the costs here are significant. Ten milliliters of Bavencio can cost more than $1,600. The cost of 180 one-milligram tablets of Inlyta can be more than $15,000. (What were the dosages used in this study? The story doesn\u2019t tell us.)", "answer": 0}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does mention the cost of treatment \u2013 $60 for 60 pills. The story should have compared this cost to the alternative \u2013 sunscreen.", "answer": 1}, {"article": "They also ate less trans fats, sugar-sweetened beverages and juice, and red and processed meat.\nThe findings paint a surprising picture of American health.\nBut other research has pinpointed a decline in death rates in this century, Wang said.\nChan School of Public Health in Boston, cautioned that it's not time to declare victory in the battle against unhealthy eating.\nAs a result, she said, it's crucial to look at a variety of studies and see if trends hold up.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We are content to declare this Not Applicable, but it wouldn\u2019t have hurt to note the financial burden and potential financial savings accrued from fewer chronic diseases and deaths and bends in the rates of disease burden. A sentence or two would have strengthened the story.", "answer": 2}, {"article": "FcMBL binds to pathogens and pathogen-released fragments, known as Pathogen-Associated Molecular Patterns (PAMPs) by recognizing carbohydrate molecules on their surface.\nTogether, the findings suggest that the FcMBL-based pathogen detection technology with its rapid handling time, high sensitivity and broad specificity towards infection-causing pathogens could provide a real-world advance to diagnose life-threatening infections in both clinical microbiology laboratories and point-of-care settings.\nNow, a Wyss Institute team led by Donald Ingber reports in eBioMedicine that it has filled this void with a rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.\n\"In our latest work, we show that the FcMBL-based pathogen-detecting assay is considerably faster and more accurate than any other available assay for systemic infection.\nThe potential of this assay to detect pathogen materials was demonstrated in both animal studies and a prospective human clinical study, whose results also suggest that it also could serve as a companion diagnostic to monitor the success of antibiotic and dialysis-like sepsis therapies.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "Given that Wyss and its start-up company have experience with the pathogen detection technology the researchers developed, there likely is by now some sense of what the cost of the assay might be, or at least some idea of whether it would be more or less expensive than current laboratory tests. It\u2019s also important to note that such a test may be associated with additional downstream costs for testing or treatment.", "answer": 0}, {"article": "UW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nThe new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nThe search committee for the Science and Medicine Graduate Research Scholars (SciMed) program director position enthusiastically announces four finalists who have been invited to give public presentations.\nThe Wisconsin Partnership Program is pleased to present its 2019-2024 Five-Year Plan, which was approved by the UW System Board of Regents in December, 2018 and goes into effect March, 2019.\nUW team shows progress in search for new antibiotics\n\nCollecting bugs across the globe is paying off for a multidisciplinary research team at the University of Wisconsin-Madison.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "The press release does not provide any indication of this drug combination cost. Since both drugs are on the market, some estimate should be possible.\nWe realize that university news releases may not be accustomed to being judged by a standard that calls for cost information. \u00a0But 70% of ~2,000 health care news stories we\u2019ve reviewed over the past 9 years were judged unsatisfactory on cost information. \u00a0So we\u2019re certainly not going to lower the bar for news releases, which could help to turn that trend around.", "answer": 0}, {"article": "(Sunlight stimulates production of vitamin D for people in sunnier climes.)\nThe recommended dietary allowance works out to three or four servings each day of \"fortified\" foods such as milk, yogurt, soy beverages, orange juice or cereal, plus fatty fish twice a week, according to Manson's commentary.\n\"Large trials of other widely used supplements have sometimes found benefits,\" Manson wrote, \"but in other cases--such as with high doses of beta carotene, vitamin E and selenium--have disproven some health claims for these supplements and identified health risks that may not have otherwise been detected.\"\nGo above 4,000 IUs, unless there's a specific reason that you need that amount, and you risk kidney stones, calcification of blood vessels and possibly the very cardiovascular disease you were seeking to prevent, Manson said in an interview.\nYou should consume modest amounts in your diet, if possible (and for most people that is quite possible), or in the form of supplements if you can't get enough via food and drink.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story does not discuss the price of vitamin D supplements (a quick online search indicates that supplements can range in price from less than $4 to more than $80 for 180 capsules). The story also says that the recommended dietary allowance of vitamin D can be met by eating \u201cthree or four servings each day of \u2018fortified\u2019 foods such as milk, yogurt, soy beverages, orange juice or cereal, plus fatty fish twice a week.\u201d Probably not an issue for most readers, but those aren\u2019t necessarily low-cost foods for people on a budget \u2014 and some of those foods may be unavailable to people who live in \u201cfood deserts.\u201d", "answer": 0}, {"article": "Those who reported longer fast durations also indicated they consumed fewer calories per day, ate fewer calories after 10 p.m. and had fewer eating episodes.\n\u201cThis is a simple dietary change that we believe most women can understand and adopt.\n\u201cIncreasing the duration of overnight fasting could be a novel strategy to reduce the risk of developing breast cancer,\u201d said Catherine Marinac, UC San Diego doctoral candidate and first author on the paper.\nThe findings were presented at the American Association of Cancer Research\u2019s annual meeting in Philadelphia.\n\u201cThe dietary advice for cancer prevention usually focuses on limiting consumption of red meat, alcohol and refined grains while increasing plant-based foods,\u201d said co-author Ruth Patterson, PhD, UC San Diego Moores Cancer Center associate director for population sciences and program leader of the cancer prevention program.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "We will rule this criterion Not Applicable in this case because the intervention in question is fasting, which costs nothing.", "answer": 2}, {"article": "In the balloon-catheter method, also known as Mammosite, a doctor inflates a balloon in the tumor cavity, and a catheter delivers the radioactive pellet.\nI think most patients want to get their treatment done as quickly as possible.\u201d\n\nAlgan said he doesn't extol one technique over the others; all are acceptable depending on the patient.\nThe computer calculates radiation exposure to nearby nerves and tissue, which is important because overexposure can cause erectile dysfunction and other problems.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nWithout the software, doctors must plan where to place the tiny pellets and then recreate the position of the prostate.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The article does not report how much the procedure costs or how it compares to conventional radiation therapy. While price would not be a driver of this decision, price information is easy and valuable to report. ", "answer": 0}, {"article": "Another is that aducanumab seems to enhance the ability of existing immune cells in the brain to devour toxins, including amyloid.\nBut there are reasons to think aducanumab may succeed where other drugs have failed.\nThose efforts have failed to produce a single approved drug so far.\nBut it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says.\nBut last summer, Biogen began presenting its results with aducanumab at scientific meetings, including the Alzheimer's Association International Conference in July.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story doesn\u2019t mention costs. However, the piece is clear that this is early-stage research that might not pan out, so we think it\u2019s acceptable that there\u2019s no cost discussion.", "answer": 2}, {"article": "Specific means that the test is unlikely to be positive if cancer isn\u2019t really present.\nThe company that developed the test, Gen-Probe, helped to pay for the study, and several authors said they had a personal financial interest in the technology.\nTo increase the accuracy of the test, researchers also looked for another gene, called prostate cancer antigen 3, or PCA3, which is also found in urine.\nThe two tests together appeared to generate both sensitive and specific results.\nBased on the levels of PCA3 and TMPRSS2:ERG detected, the men were given numerical scores that were classified as being high, medium, or low.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Although the story included price estimates for prostate biopsy, it did not include a ball park estimate for the cost to assay for the gene fusion product discussed nor the costs of testing for PCA3, which is currently commercially available.", "answer": 0}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Statins are described as \u201ccheap,\u201d but actual figures are not provided.\u00a0The price of statins varies considerably and some are not cheap. ", "answer": 0}, {"article": "\u201cThe question has been, \u2018What do you do with the rest?\u2019\u201d he says.\nSimilar to treatment with thalidomide, most of the patients had a relapse of their skin problems within weeks of stopping the drug.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\nIn a small study from Spain, lupus patients showed dramatic improvements in skin lesions while taking the drug, lenalidomide (Revlimid), and most relapsed soon after they stopped taking it.\nDec. 7, 2012 -- A drug related to thalidomide may be more potent and less toxic than thalidomide, which is often used to treat lupus skin conditions.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Brief discussion of costs at the end of the story; however, costs were mentioned in relation to conditions for which lenalidomide\u00a0is currently approved to treat (and the costs were taken from the manufacturer\u2019s website). \u00a0If patients use lenalidomide\u00a0for treatment of lupus skin conditions, which at the moment is off-label use, the patient could be responsible for total cost.", "answer": 1}, {"article": "A viral vector is a virus that has been modified to deliver foreign genetic material into a cell.\nThe boy is currently on chemotherapy, the study authors noted.\n\"Transplants are getting better but we need better therapy, there's no question.\"\n\"But they're not an easy group of patients to transplant.\"\n\"It's a good start, but I think we have better things coming down the road.\"\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "We think it\u2019s too early to guess at what any therapy based on this technique would cost, so we won\u2019t flag the story for not mentioning costs.", "answer": 2}, {"article": "Studies with animals have shown memory improvement, but there is debate about the impact of calorie restriction on humans\u2019 cognitive function.\nThe other groups showed no significant change.\nA third group made no dietary changes.\nThen they took tests involving memorizing words.\nThe calorie-restricted group averaged 20 percent improvement in memory performance.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "Cost is not a major issue in this story. ", "answer": 2}, {"article": "During the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nThat led some experts to suggest that weight loss and exercise should be the next frontier for cancer prevention research.\nAll the women had been successfully treated for early-stage breast cancer.\n\"It sends us back to the drawing board,\" said Susan Gapstur of Northwestern University's Feinberg School of Medicine, who co-wrote an accompanying editorial.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "There was no discussion of the cost of fresh fruit and vegetables compared to the typical American diet of largely processed/fast foods.\u00a0 But it\u2019s safe to assume most readers know the costs from their regular grocery shopping. ", "answer": 2}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story notes that a whole-body DXA scan costs \u201c$45 to $350 or more\u201d and is generally not covered by insurance. While readers can do the math,\u00a0it would have been very useful for the story to point out what the costs of scanning at the intervals suggested (up to every 3 months) would amount to over time.", "answer": 1}, {"article": "It's crazy enough to laugh off.\nBut rather than stocking up on the sugar-rich chocolate bars at the checkout line, researchers believe the starting point is to look for ways to take the compound out of cocoa, make more of it and then use it as a potential treatment for current diabetes patients.\nThe new study, published in the Journal of Nutritional Biochemistry, finds beta cells work better and remain stronger with an increased presence of epicatechin monomers, compounds found naturally in cocoa.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n", "question": "Does the news release adequately discuss the costs of the intervention?", "explanation": "This line of research is only at the most basic conceptual level so cost projections are unrealistic. However, there is an undercurrent in the message that suggests that this particular fraction of cocoa could be turned into a drug. When the release states that \u201cresearchers believe the starting point is to look for ways to take the compound out of cocoa, make more of it and then use it as a potential treatment for current diabetes patients\u201d it suggests big profits for a drug company, not the cocoa bean growers of South America.", "answer": 2}, {"article": "Subsequently, a clinician will help a patient learn to slow down or speed up those brain waves, through a process known as operant conditioning.\nThe findings prompted a boomlet of interest in which clinicians of varying degrees of respectability jumped into the field, making many unsupported claims about seeming miracle cures and tainting the treatment\u2019s reputation among academic experts.\nWilliam E. Pelham Jr., director of the Center for Children and Families at Florida International University, called neurofeedback \u201ccrackpot charlatanism.\u201d He warned that exaggerated claims for it might lead parents to favor it over proven options like behavioral therapy and medication.\nDr. Norman Doidge, a psychiatrist at the Center for Psychoanalytic Training and Research at Columbia and the author of \u201cThe Brain That Changes Itself\u201d (Viking, 2007), said he considered neurofeedback \u201ca powerful stabilizer of the brain.\u201d Practitioners make even more enthusiastic claims.\nRobert Coben, a neuropsychologist in Massapequa Park, N.Y., said he had treated more than 1,000 autistic children over the past seven years and had conducted a clinical study, finding striking reductions in symptoms, as reported by parents.\n", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "\u00a0The story provided cost estimates for a couple of neurofeedback treatment regimens. \u00a0It also indicated euphemistically that it is not paid for by insurance companies.", "answer": 1}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story adequately discuss the costs of the intervention?", "explanation": "The story did not discuss costs, and this was a missed opportunity. Cigarette smoking creates a huge burden on our health care system. The cost of the gum \u2013 $50 to $70 for a box of 100 pieces \u2013 may be a drop in the bucket compared to the costs of people developing cancer and other disorders from smoking.\u00a0 A study mentioned in the story has a nice section on costs that we wish the story had quoted: \u201c\u2026the incremental cost of extended versus standard therapy was $2482 per additional quitter at 24 weeks.\u201d", "answer": 0}]